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ABSTRACT 
 
Invasive fungal infections (IFIs) have increased significantly over the last decades. 
Amphotericin B (AMB) represents a very important therapeutic option for the treatment of these 
infections. Interestingly, despite more than 50 years of use in clinical setting, emergence of 
resistance to AMB is an extremely rare event. However, although the often confirmed in vitro 
susceptibility, the clinical response to AMB is sometimes reduced. While AMB is effective as a 
fungicidal drug, several factors can impair its clinical utility, namely underlying diseases, other 
concomitant administered drugs, timing of antifungal therapy, as well as AMB pharmacokinetics 
and distribution. The present study sought to understand this long-standing question in a 
biological perspective. It was evaluated the cascade of functional changes occurring in yeast cells, 
induced by exposure to liposomal amphotericin B (L-AMB), in a variable concentration simulating 
the human plasma concentration, along 24 h. Indeed, under such condition, yeast cells developed 
compensatory responses at distinct levels like membrane permeability, metabolic activity, and 
production of endogenous reactive oxygen species (ROS) during the first 6 h after the exposure 
to high plasma concentrations (20 to 5 mg/L); in the remaining 18 h, when exposed to much lower 
L-AMB concentrations (at or below minimal inhibitory concentration [MIC]), cells revealed almost 
full recovery with no evidence of fungicidal activity. These results highlighted the importance of 
monitoring and maintaining L-AMB at sufficient concentrations in plasma and tissue to ensure it 
produces its fungicidal effect.  
Different strategies aiming to improve the clinical efficacy of AMB were also explored. 
Combined antifungal therapy could be a promising approach for the treatment of IFIs. However, 
late diagnosis and poor clinical response to antifungal monotherapy frequently promote the use 
of empirical antifungal combination as salvage therapy, even without scientific base. Since the 
methodologies available for in vitro evaluation of drug associations are very laborious, and thus 
not compatible with the daily routine of the microbiology laboratory, it was developed a novel 
assay using flow cytometry, based upon the classic checkerboard method. A cytometric algorithm 
was determined for the classification of the association between anidulafungin (AND) and AMB 
or azoles against yeasts as synergistic, indifferent, or antagonistic interaction. This novel protocol 
exhibited high agreement with the traditional checkerboard method, having the advantage of 
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providing quantitative results in less than 2 h. A large number of Candida isolates with distinct 
susceptibility patterns to AND, AMB and azoles, was evaluated using this new protocol. The 
association of AND with AMB or azoles was synergistic for a vast amount of the isolates tested. 
However, an indifferent effect was frequently found, and a few cases of antagonism occurred. 
Although this therapeutic approach seems to be promising, these results stress that the 
association of antifungal drugs should be conveniently evaluated in vitro before its clinical use.   
Likewise, the combination of antifungals with antibacterial agents deserved a particular 
attention. The combination of L-AMB with several antibacterial agents was investigated. The 
association of compounds that act by inhibiting RNA/protein synthesis, namely rifampicin, 
azithromycin, clarithromycin, and tetracycline with L-AMB was synergistic against Candida spp. 
and Aspergillus fumigatus. The most effective association involved L-AMB and colistin (CST), a 
drug that acts by disrupting the cell membrane of gram-negative bacteria. This association was 
investigated at a functional and molecular level. Molecular dynamics studies demonstrated that 
CST forms a stable complex with L-AMB acting together in the fungal membranes. The formation 
of this complex enhanced and catalyzed the fungicidal activity of L-AMB, as demonstrated by 
functional studies.   
In summary, this dissertation presented a comprehensive analysis of the AMB fungicidal 
activity and the fungal cell recovery mechanisms, that may justify the fungal survival and treatment 
failure. In addition, it elucidated about the potential beneficial effects of the combined therapy, 
either involving antifungal or antibacterial compounds.  
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RESUMO 
 
As infecções fúngicas invasivas (IFIs) aumentaram significativamente nas últimas 
décadas. A anfotericina B (AMB) representa uma opção terapêutica muito importante para o 
tratamento destas infecções. Curiosamente, após mais de 50 anos de uso na prática clínica, a 
emergência de resistência à AMB é um evento extremamente raro. Apesar de ser 
frequentemente confirmada susceptibilidade in vitro, a resposta clínica à AMB é por vezes 
reduzida. Embora a AMB seja um fármaco fungicida, vários factores podem comprometer a sua 
eficácia clínica, nomeadamente doenças subjacentes, outros fármacos concomitantemente 
administrados, assim como o seu perfil farmacocinético. O presente estudo procurou 
compreender esta questão numa perspectiva biológica. Foi avaliada a cascata de alterações 
funcionais que ocorreram nas células de levedura, induzidas pela exposição à anfotericina B 
lipossómica (L-AMB), numa concentração variável que simula a concentração plasmática 
humana, ao longo de 24 horas. De facto, nestas condições, as células de levedura 
desenvolveram respostas compensatórias a níveis distintos, tais como permeabilidade de 
membrana, actividade metabólica e produção endógena de espécies reactivas de oxigénio 
(ROS), durante as primeiras 6 horas após a exposição a concentrações plasmáticas elevadas 
(20 a 5 mg/L); nas restantes 18 horas, quando expostas a concentrações de L-AMB muito 
menores (iguais ou inferiores à concentração mínima inibitória), as células mostraram 
recuperação quase completa, não havendo evidência da actividade fungicida do fármaco. Estes 
resultados destacaram a importância de monitorizar e manter a L-AMB em concentrações 
suficientes no plasma e nos tecidos, para garantir que esta exerce a sua actividade fungicida.  
Foram também exploradas diferentes estratégias com o objectivo de melhorar a eficácia 
clínica da AMB. A terapêutica antifúngica combinada poderá ser uma abordagem promissora 
para o tratamento das IFIs. No entanto, o diagnóstico tardio e a pobre resposta clínica à 
monoterapia antifúngica promovem frequentemente o uso da combinação empírica de 
antifúngicos como terapêutica de salvação, mesmo sem base científica. Uma vez que as 
metodologias disponíveis para a avaliação in vitro das associações de fármacos são muito 
trabalhosas e, por isso, incompatíveis com a rotina diária de um laboratório de microbiologia, foi 
desenvolvido um novo ensaio por citometria de fluxo, baseado no método clássico checkerboard. 
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Foi determinado um algoritmo citométrico para a classificação da associação entre a 
anidulafungina (AND) e a anfotericina B ou azoles contra leveduras como uma interação 
sinérgica, indiferente ou antagonista. Este novo protocolo revelou uma elevada concordância 
com o método tradicional checkerboard, tendo a vantagem de fornecer resultados quantitativos 
em menos de 2 horas. Um grande número de isolados do género Candida com diferentes 
padrões de susceptibilidade à AND, AMB e azoles, foi avaliado usando este novo protocolo. A 
associação da AND com AMB ou azoles foi sinérgica para grande parte dos isolados testados. 
No entanto, foi frequentemente encontrado um efeito indiferente e raros casos de antagonismo. 
Embora esta abordagem terapêutica pareça ser promissora, estes resultados salientam que a 
associação de fármacos antifúngicos deve ser convenientemente avaliada in vitro antes da sua 
utilização clínica.  
Do mesmo modo, a combinação de antifúngicos com agentes antibacterianos mereceu 
uma atenção particular. A combinação da L-AMB com vários agentes antibacterianos foi 
investigada. A associação de compostos que actuam pela inibição da síntese de RNA/proteínas, 
nomeadamente rifampicina, azitromicina, claritromicina e tetraciclina com L-AMB foi sinérgica 
contra Candida spp. e Aspergillus fumigatus. A associação mais eficaz envolveu L-AMB e 
colistina (CST), um fármaco que actua na membrana celular de bactérias gram negativo. Esta 
associação foi investigada a nível funcional e molecular. Estudos de dinâmica molecular 
demonstraram que a CST forma um complexo estável com a L-AMB, atuando em conjunto na 
membrana da célula fúngica. A formação deste complexo potenciou e catalisou a actividade 
fungicida da L-AMB, como demonstrado pelos estudos funcionais.  
Em resumo, esta dissertação descreve uma análise abrangente da actividade fungicida 
da AMB e dos mecanismos de recuperação da célula fúngica, os quais podem justificar a sua 
sobrevivência e a falha da terapêutica. Além disso, elucida sobre os potenciais efeitos benéficos 
da combinação de fármacos, envolvendo compostos antifúngicos e antibacterianos.   
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AIMS OF THE STUDY 
 
Despite the clinical success of amphotericin B (AMB) an insufficient response is 
sometimes reported.  The aims of the present work address the fungal survival mechanisms in 
response to decreasing concentrations of AMB, simulating those obtained in human plasma, and 
to investigate strategies to improve AMB efficacy, namely antimicrobial associations. Flow 
cytometric studies were performed in order to characterize different physiological statuses 
induced by single AMB exposure, and in association with other antimicrobial drugs. In addition, 
computational molecular dynamics studies were carried out, aiming to unveil the underlying 
mechanisms of the association between AMB and synergic antimicrobials.  
 
The specific aims of the present work were: 
i. To investigate the mechanism of yeast “escape” to AMB effect, by studying the different 
physiological statuses induced by AMB exposure at decreasing concentrations, along a 
timeframe; 
ii. To determine whether cell survival following AMB exposure is a phenomenon transversal 
through different yeast species, some of which have serious clinical implications;  
iii. To develop a new, rapid and convenient method to evaluate antifungal associations, 
validating its in vitro efficacy; 
iv. To improve AMB efficacy by proposing antibacterial compounds that may act 
synergistically with AMB, enhancing its fungicidal effect; 
v. To characterize the AMB/most additive antimicrobial association at a phenotypic and 
functional level, and to unveil the mechanisms of synergism using computational molecular 
dynamics simulations.  
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OUTLINE OF THE THESIS 
 
The present dissertation is divided in chapters, which include the different manuscripts 
published in international peer reviewed journals and works presented throughout the doctoral 
program in international conferences as poster presentations or abstracts published online. 
 
Chapter I details the aims of the work and presents a brief explanation of the structure of the 
thesis, in order to facilitate the reading and understanding of the text.  
 
Chapter II corresponds to the introduction section. This chapter presents the most important facts 
published in the last years related to the present work. It constitutes a theoretical background to 
support the understanding and the future discussion of the information presented in the following 
chapters.  
 
Chapter III includes the second paper published in an international peer reviewed journal. It 
describes, for the first time, the yeast physiological mechanisms of liposomal amphotericin B (L-
AMB)-induced action at plasma concentrations and a constant fixed concentration, along a 
timeframe. The mechanism of yeast survival to L-AMB action was explored and it has been shown 
that yeast cells can respond to L-AMB following different perspectives; the adoption of different 
stress responses can allow its full recovery.  
 
Chapter IV includes the first paper published in an international peer reviewed journal. It 
describes a rapid alternative method to conventional approaches to test antimicrobial drug 
interactions. The flow cytometric protocol was developed to evaluate critical antifungal 
associations like amphotericin B or azoles with the echinocandin anidulafungin.  
 
Chapter V includes the third paper, published in an international peer reviewed journal. It 
describes the improvement of the fungicidal effect of liposomal amphotericin B at subinhibitory 
concentrations when combined with distinct antibacterial drugs. The most synergic interaction 
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was scrutinized and the underlying mechanism characterized at a phenotypic, functional and 
molecular level. 
 
Chapter VI includes a global discussion of the different studies presented in the previous 
chapters.  
 
Chapter VII presents the general conclusions of this dissertation and describes the future 
perspectives aiming to establish new research topics based on the current findings for a more 
comprehensive study of AMB action, at a biological and clinical level.  
 
Chapter VIII lists the bibliography accessed throughout the development of the work and thesis.  
 
Chapter IX includes the publications associated to the present dissertation. 
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EPIDEMIOLOGY OF INVASIVE FUNGAL INFECTIONS 
 
Over the past two decades, the incidence of invasive fungal infections (IFIs) has 
increased significantly in nosocomial settings throughout the world (Pfaller et al., 2006; Pfaller 
and Diekema, 2007; Richardson and Lass-Florl, 2008). The emergence of such infections 
invariably associated with substantial morbidity and mortality rates, is directly related to: i) the 
increase of populations at risk, including haematopoietic stem cell transplant, solid organ 
transplant recipients, patients with neoplastic disease, HIV/AIDS, advanced age (>70 years), 
intensive care unit (ICU), surgical and burn patients (Pfaller et al., 2006; Lass-Florl, 2009); ii) the 
increased use of immunosuppressive and antineoplastic agents or broad-spectrum antimicrobials 
for a better control of underlying diseases (Pfaller and Diekema, 2007; Richardson and Lass-Florl 
2008; Lass-Florl, 2009); and iii) the developments in the medical field and the practice of a more 
interventionist medicine, which resulted in improved survival of individuals with life-threatening 
illnesses, but has also contributed to a higher risk of acquisition of opportunistic fungal infections 
(Richardson, 2005; Shao et al., 2007; Lass-Florl, 2009). 
Species of Candida and Aspergillus remain the most common causes of invasive fungal 
infections. However, the epidemiology of IFIs has shifted in recent years as Zygomycetes, 
Fusarium spp. and Scedosporium spp. have become increasingly important pathogens (Lai et al., 
2008; Richardson and Lass-Florl, 2008; Oren and Paul, 2014). The reasons for the changing 
epidemiology of IFIs are not entirely known, but possibly are related to patient demographics and 
comorbidities, changes in treatment strategies, and the increased use of antifungal prophylaxis 
(Lass-Florl, 2009).  
The complexity of the risk population and the diversity of fungal pathogens taken together 
with difficult and late diagnosis of IFIs often result in a poor clinical outcome, despite the antifungal 
treatment.  
 
Candida species 
Candida is a common inhabitant of the normal human ﬂora (e.g. skin, gastrointestinal 
tract, genitourinary tract) and is also found in the environment. Despite the main reservoir of 
Candida (particularly C. albicans) is endogenous, infections can also arise from exogenous 
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sources (Pfaller et al., 2006). Candidosis can manifest as a wide range of clinical pictures, from 
mucocutaneous to bloodstream infections (BSIs), being the latter the most frequent manifestation 
of invasive candidosis (Pfaller et al., 2006; Lass-Florl, 2009).  
Over the last 20 years, Candida spp. have become the fourth leading cause of BSIs, 
accounting for 8% to 10% of all BSIs acquired in hospital (Pfaller and Diekema, 2007; Oren and 
Paul, 2014). The annual incidence of Candida-associated BSIs ranged from 6 to 23 per 100 000 
persons in the USA, and from 2.53 to 11 per 100 000 persons in European countries (Clark et al., 
2004; Hajjeh et al., 2004; Pfaller et al., 2006; Tortorano et al., 2006). The European Confederation 
of Medical Mycology (ECMM) survey conducted between 1997 and 1999, reported rates of 0.20 
to 0.38 per 1000 admissions by participating countries (France, Germany/Austria, Italy, Spain, 
Sweden and UK) (Tortorano et al., 2006). A French study performed between 2001-2002 has 
described an annual incidence of candidemia of 6.7 per 1000 admissions (Bougnoux et al., 2008). 
In Spain, the number of candidemia episodes between 2000 to 2009 has increased from 0.57 per 
1000 admissions per year in 2000 to 1.52 in 2009 (Fortún et al., 2012); then, decreased to 0.89 
per 1000 admissions between 2010 and 2011 (Puig-Asensio et al., 2014). In Portugal, the 
incidence of fungemia has decreased from 2.7 per 1000 admissions in 2004 to 0.88 in 2012, 
being 95% of such infections caused by Candida spp. (Costa-de-Oliveira et al., 2008; Faria-
Ramos et al., 2014).  
Population at risk for candidemia includes mostly patients admitted in the ICU, patients 
with solid or haematological malignancy and those undergoing abdominal surgery mainly 
involving the colon. Mucous membrane colonization seems to be a requisite for development of 
IFIs due Candida species, being significantly increased among critically ill patients receiving 
broad-spectrum antibiotics (Lass-Florl, 2009). Other risk factors for acquisition of invasive 
candidosis include the use of intravascular devices, catheters and parenteral nutrition, 
neutropenia, and the combination of such risk factors (Lass-Florl, 2009; Oren and Paul, 2014). 
Candida albicans is the main cause of candidemia worldwide and was responsible for 
more than half of cases of infection in several reports (Pfaller et al., 2006; Tortorano et al., 2006; 
Lass-Florl, 2009). However, its relative frequency is decreasing, while the frequency of the non-
albicans Candida species such as C. glabrata, C. parapsilosis, C. tropicalis and C. krusei is 
increasing as causative pathogens in BSI (Lass-Florl, 2009; Oren and Paul, 2014). Candida 
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species distribution is influenced by geographical area and patient’s characteristics. C. glabrata 
infections are more common in the elderly; C. parapsilosis is more common in children and 
neonates, while C. tropicalis in patients with cancer, especially leukemia and among patients with 
neutropenia. C. krusei is frequent in immunocompromised patients and similar to C. tropicalis, in 
patients with neutropenia (Pfaller et al., 2006; Oren and Paul, 2014). In the Candida Surveillance 
Study conducted between 2004 and 2007, the distribution of Candida species in United States 
was C. albicans the most prevalent species with 43.5%, followed by C. glabrata with 24.8%, C. 
parapsilosis with 17.8%, C. tropicalis with 8.9%, C. krusei with 1.9%, C. lusitaniae with 1.3%, and 
other Candida species with 1.9% (Lyon et al., 2010). In the ECMM survey, the incidence rates for 
non-albicans species were 14% each for C. glabrata and C. parapsilosis, 7% for C. tropicalis and 
2% for C. krusei (Tortorano et al., 2006). A Portuguese multicenter survey conducted between 
2011 and 2012, has reported the following Candida species distribution: C. albicans with 40.4%, 
C. parapsilosis with 22.9%, C. glabrata with 13.3%, C. tropicalis with 6.3%, and C. krusei with 5% 
(Faria-Ramos et al., 2014). In several reports, the use of prophylactic fluconazole is described as 
a risk factor for non-albicans species, e.g. C. krusei and C. glabrata (Lass-Florl, 2009; Pfaller et 
al., 2014). 
The reported mortality rates from Candida fungaemia range from 28% to 42% in United 
States, and from 28 to 59% in European surveys, and depend on the species and geographical 
location (Tortorano et al., 2006; Lass-Florl, 2009; Ha et al., 2012).  
 
Aspergillus species 
Aspergillus species are ubiquitous in water, soil, food and decaying materials. Their 
spores are frequently inhaled by humans (Shao et al., 2007; Gregg and Kauffman, 2015; Gautier 
et al., 2016). Aspergillosis encompasses a broad spectrum of diseases, including allergic 
bronchopulmonary aspergillosis, aspergilloma, chronic necrotizing aspergillosis, and invasive 
aspergillosis (IA) (Perfect et al., 2001). Invasive aspergillosis is a serious opportunistic infection 
and the second most common IFI, its incidence having increased over the last 20 years 
(Meersseman and Wijngaerden, 2007; Oren and Paul, 2014). The IA incidence is probably 
underestimated due to limitations in the diagnosis of this infection; it varies according with patient 
population and their environment, reaching rates of 7% in Europe (Lass-Florl, 2009; Meersseman 
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et al., 2004). The main affected population involves neutropenic patients with haematological 
malignancies (5 - 24%) and/or those receiving haematopoietic stem cell transplantation (2 - 26%) 
(Weber et al., 2009; Nicolle et al., 2011); patients with chronic granulomatous disease (25 – 40 
%) (Denning et al., 1998), patients receiving solid organ transplantation (1 – 15%) or advanced 
acquired immunodeficiency syndrome (0.5 - 10 %) (Denning et al., 1998; Tong et al., 2009; Weber 
et al., 2009). Risk factors for IA including neutropenia, antibiotic therapy, corticosteroid therapy, 
cytotoxic chemotherapy, and other immunosuppressive agents (Maschmeyer et al., 2007; Shao 
et al., 2007; Lass-Florl, 2009; Gregg and Kauffman, 2015).  
Although Aspergillus fumigatus is the most common cause of aspergillosis, non-
fumigatus Aspergillus species such as A. flavus, A. niger and A. terreus are becoming more 
frequent (Shao et al., 2007; Lass-Florl, 2009). According with an international multicenter study 
conducted between 2000 and 2011 in critically ill patients, the incidence rates for Aspergillus 
species were: 92% for A. fumigatus, 3% for A. flavus, 1% for A. niger and 3% for another 
Aspergillus spp. (Taccone et al., 2015).  
Mortality rates of IA are very high (50-95%), partly due to diagnostic difficulties, limited 
antifungal treatment options, underlying diseases of patients at risk, and also due to the lack of 
understanding of virulence factors involved in fungal pathogenicity and possible interaction of the 
pathogen with the host immune system (Binder and Lass-Florl, 2013).  
 
Zygomycetes 
Zygomycetes have emerged as increasingly important pathogens associated with high 
mortality rates (up to 90%) (Petrikkos et al., 2014). Microorganisms belonging to the order 
Mucorales (e.g. Rhizopus, Mucor, Rhizomucor) are most frequently implicated in human disease 
(Lass-Florl, 2009). Mucormycosis is the second most frequent invasive mould infection and its 
incidence increased from 0.7 per million in 1997 to 1.2 per million in 2006, in Europe (Petrikkos 
et al., 2014).  
The host risk factors for mucormycosis including malignant hematological disease, 
prolonged and severe neutropenia, poorly controlled diabetes mellitus, iron overload, burns, and 
prolonged use of corticosteroids (Lass-Florl, 2009; Petrikkos et al., 2014). The clinical 
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manifestations and outcome of these infections is determined by the underlying diseases of 
patients (Petrikkos et al., 2012).  
 
ANTIFUNGAL THERAPY 
 
The therapeutic options for invasive fungal infections are narrow, comprising only four 
chemical classes, divided according to their mechanism of action (Perlin et al., 2015).  
The polyenes, the most important member of which is amphotericin B (AMB), bind to 
ergosterol (the major sterol in the fungal cell membranes), and form complexes that induce 
membrane damage (Figure 1). The polyene antibiotics have broad antifungal activity against 
microorganisms ranging from yeasts to filamentous fungi (Carrillo-Muñoz et al., 2006).  
The azoles, i.e., fluconazole (FLU), voriconazole (VOR), posaconazole (POS), impair 
sterol biosynthesis by inhibiting sterol 14α-demethylase, which results in ergosterol depletion and 
accumulation of toxic methylated sterols (Figure 1). Fluconazole is one of the antifungal agents 
mostly used in both prophylactic and therapeutic protocols (Tortorano et al., 2006). Its spectrum 
of activity includes C. albicans, most strains of C. tropicalis, and C. parapsilosis. Conversely, C. 
krusei is intrinsically resistant, and C. glabrata demonstrates reduced susceptibility to FLU 
(Tortorano et al., 2006). Voriconazole is indicated for the primary treatment of aspergillosis, for 
salvage therapy in case of severe fungal infections due to Fusarium sp. and Scedosporium sp., 
and in patient’s refractory or intolerant to other antifungals. It exhibits a large spectrum of activity 
against Candida spp., including C. krusei and C. glabrata (Johnson and Kaufman, 2003; 
Kontoyiannis et al., 2005). Posaconazole has a broad spectrum of activity towards yeasts, 
filamentous and dimorphic fungi. However, it is less active in vitro against FLU-resistant Candida 
spp., especially C. glabrata and C. krusei (Nagappan and Deresinski, 2007). 
The echinocandins, i.e., anidulafungin (AND), caspofungin (CSF), micafungin (MCF), 
target the 1,3-β-D-glucan synthase, an enzyme necessary for synthesis of 1,3-β-D-glucan, an 
important constituent of the fungal cell wall, impairing cell wall synthesis. This antifungal class 
exhibits good in vitro and in vivo activity against a range of Candida species and is recommended 
as an alternative for Aspergillus infections (Perlin, 2011).  
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Finally, the pyrimidine analog flucytosine, which is taken up into the cell by a specific 
transporter and then converted into 5-fluoro-uridine monophosphate by the sequential action of 
the enzymes cytosine deaminase and uracil phosphoribosyltransferase, causes the production of 
toxic nucleotides and disruption of DNA and protein synthesis (Figure 1). 5-Flucytosine (5-FC) 
remains an option for the treatment of Candida infection which are life threatening or in the cases 
where drug penetration may be problematic (Hope et al., 2004). However, monotherapy with 5-
FC is limited due to the frequent development of resistance and its narrow spectrum of activity 
(Vermes et al., 2000). 
 
Figure 1 -  Mechanism of action of antifungal drugs available for the treatment of invasive fungal infections. 
Polyenes bind to ergosterol, a main component of the cell membrane, forming pores in the membrane. Azoles antifungals 
inhibit the enzyme lanosterol 14α-demethylase, involved in the synthesis of ergosterol. This inhibition leads to the 
production of toxic compounds altering cell membrane structure and permeability. Echinocandins inhibit the enzyme 1,3-
β-D-glucan synthase leading to alterations in the cell wall structure. Pyrimidine analogues induce the production of toxic 
compounds that interfere with the nucleic acid and protein synthesis. 
 
However, many of these antifungal drugs demonstrate reduced clinical efficacy, high 
toxicity, and are prone to the development of resistance, what limit the antifungal options, and 
result in a poor clinical outcome (Zeidler et al., 2013).  
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AMPHOTERICIN B: A MILESTONE IN ANTIFUNGAL THERAPY 
 
Despite the availability of new antifungal drugs over the last thirty years, amphotericin B 
(AMB) has remained as the last line of defense in the treatment of life-threatening systemic fungal 
infections (Gray et al., 2012; Anderson et al., 2014). AMB is produced naturally by Streptomyces 
nodosus and was first isolated in 1955 by Gold et al. (Gold et al., 1955). Its molecular structure is 
characterized by a lactone ring with 38 carbon atoms, encompassing a hydrophilic and a 
heptaenic chains parallel to each other (Figure 2). The hydrophilic chain of AMB contains several 
hydroxyl groups; in the “polar head” of the molecule are situated carboxyl and mycosamine groups 
(C16 and C19, respectively); in the hydrophobic portion of the molecule at position C35 another 
hydroxyl group is located, which confers amphiphilic properties to the AMB molecule (Figure 2) 
(Sternal et al., 2004; Mouri et al., 2008). This polyene has been one of the most widely used 
antifungal drug worldwide in the clinical practice, due to its broad spectrum of fungicidal activity, 
and extremely rare acquisition of resistance. Its use along more than 50 years is a case study in 
clinical medicine. However, its use is somewhat hampered by the incidence of side effects such 
as nephrotoxicity. Additionally, AMB exhibits hepatotoxic activity, and in higher doses neurotoxic 
and hemolytic activities (Gagós and Arczewska, 2010). Such faits render the conventional 
amphotericin B deoxycholate formulation unsuitable for treatment. In an attempt to improve the 
delivery of the drug and the therapeutic index of amphotericin B, three lipid-associated 
formulations were developed, including liposomal amphotericin B (L-AMB), amphotericin B lipid 
complex, and amphotericin B colloidal dispersion. The lipid composition of all three of these 
preparations differs considerably and contributes to different pharmacokinetic parameters (Hamill, 
2013).  
 
Mechanism of action 
Studies on amphotericin B mechanism of action revealed that its antifungal activity is very 
complex. For decades, the prevailing mechanism of action has been that AMB binds to ergosterol, 
inserting into the fungal cytoplasmic membrane, and forms pore-like structures, resulting in 
osmotic instability, loss of membrane integrity, metabolic disruption, ultimately killing fungal cells 
(Gray et al., 2012; Anderson et al., 2014; Gonçalves et al., 2016). Additional studies also propose 
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the hypothesis that AMB induces common oxidative damage death pathways (Belenky et al., 
2013). 
 
Figure 2 - Models for the structure and function of amphotericin B. (A) Molecular structure of AMB. (B) 
The classic ion channel model for the structure and function of AMB. (C) A new sterol sponge model, in 
which AMB primarily exists in the form of large extramembranous aggregates that extract ERG from lipid 
bilayers (Anderson et al., 2014). 
 
Transcriptomic studies supported the classic AMB action; it was demonstrated that AMB 
induced alterations in expression of genes involved in cell stress, membrane reconstruction, 
transport, and cell wall integrity (Zhang et al., 2002; Agarwal et al., 2003; Liu et al., 2005; Ko et 
al., 2009). Proteomic analysis has been also used to unveil the adaptive response of Candida to 
AMB. Hoehamer et al., have demonstrated that exposure to AMB impaired the abundance of 43 
proteins, including those associated with oxidative stress, osmotic tolerance, and carbohydrate 
metabolism (Hoehamer et al., 2010). The changes of these functional classes of genes/proteins 
are consistent with the mechanism of action previously proposed. According to this model, the 
cytotoxic activity of AMB is dependent on the ion channel-forming (Anderson et al., 2014). 
Importantly, it has long been known that lipid membranes containing sterols are extremely 
vulnerable to permeabilization by AMB, being the AMB affinity higher for ergosterol (ERG) 
compared with its affinity for cholesterol; however, there was the doubt whether AMB effect was 
due to indirect sterol-mediated general changes in membrane properties or direct sterol binding. 
 Recent structural, molecular and biophysical studies, including computer modeling, 
spectroscopy, microscopy, show that the channel forming capacity of AMB is not required for 
fungicidal activity, whereas binding ergosterol is crucial (Bolard, 1986; Baginski et al., 2002; 
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Milhaud et al., 2002; Volmer et al., 2010). Indeed, the ergosterol plays an important role in fungal 
cell physiology such as vacuole fusion, cell division, endocytosis, cell signaling, membrane 
compartmentalization, and functional regulation of membrane proteins. Therefore, ergosterol 
binding prevents its participation in multiple cellular functions, thus leading to fungal cell death. 
These studies suggest that AMB primarily kills fungal cells by simply binding ergosterol, and the 
membrane permeabilization via channel formation represents a second complementary 
mechanism that further increases drug potency and the rate of yeast killing. Anderson et al. have 
explored the primary structure and function of AMB in the presence or ERG-containing 
phospholipid membranes and reported that AMB exists primarily in the form of large, 
extramembranous aggregates, which kill fungal cells by extracting ergosterol from lipid 
membranes (Figure 2) (Anderson et al., 2014). The membrane-inserted ion channels are 
relatively minor contributors, both structurally and functionally, to the antifungal action of this 
natural product. Moreover, the ion channels formation is strongly dependent on the molecular 
organization of AMB; only AMB dimers and N-aggregates can cross through the lipid membrane 
(Gagós and Arczewska, 2010).  
 
Pharmacokinetics and distribution 
The effectiveness of the treatment of fungal infections depends on the drug 
pharmacokinetics and distribution and its adequate penetration and retention at the sites of 
infection. Liposomal amphotericin B (AmBisome) is a lipid formulation that consists in 
amphotericin B in small, unilamellar lipossomes (Bekersky et al., 2002). Amphotericin B lipid 
formulation is safer than conventional AMB (amphoterin B deoxycholate), having the advantage 
to alter the disposition of AMB in the body and thereby decrease the toxic side effects. The 
reduced toxicity of L-AMB allows to increase the dose and may contribute to improved antifungal 
effectivity (Heinemann et al., 1997). Data on the pharmacokinetics of L-AMB are scarce in the 
literature. However, studies in animals and humans have shown that liposomal amphotericin B 
results in higher drug levels in plasma than other formulations as well as higher levels of 
amphotericin B in tissue (Walsh et al., 1998; Bekersky et al., 2002). This is a result of the unique 
composition of the L-AMB liposomes, which contain rigid, charged phospholipids and cholesterol 
to retain amphotericin B within the bilayer membranes of the circulating liposomes. Liposomal 
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AMB remains unchanged in the circulation and distributes as intact liposomes to tissues (Adler-
Moore and Proffitt, 1993, 1998). Therefore, the pharmacokinetics of L-AMB differ significantly 
from those of conventional AMB. According with a study performed by Bekersky et al. in healthy 
volunteers, the plasma concentrations during the first 24h are 8- to 16-fold higher with L-AMB 
(Cmax, 22.9 ± 10 mg/L) than with amphotericin B deoxycholate (Cmax, 1.4 ± 0.2 mg/L); although 
the two formulations had similar half-lives, the urinary and fecal clearances (CL) of L-AMB are 
10-fold lower than those of AMB deoxycholate (Bekersky et al., 2002). Another study involving 
critically ill patients has demonstrated that when the patients were administrated L-AMB in a dose 
3-fold higher than AMB deoxycholate, the median Cmax and AUC values were 8.4-fold (14.4 versus 
1.7 mg/L) and 9-fold (171 versus 18.65 mg · h/L) higher, respectively, for L-AMB than for AMB 
deoxycholate. This study also has demonstrated that the median V (volume of distribution) and 
CL were lower for L-AMB than for AMB deoxycholate (Heinemann et al., 1997). Walsh et al., in a 
study with neutropenic patients obtained similar results (Walsh et al., 1998). The authors have 
suggested that the low volume of distribution of L-AMB occurs due to a decreased interaction of 
AMB with proteins and/or membrane cholesterol, which contribute to a greater peak plasma 
concentrations and AUC values; the reduced clearance might be related with the fact that L-AMB 
is eliminated from plasma mainly by the reticuloendothelial system (Heinemann et al., 1997; 
Walsh et al., 1998; Bekersky et al., 2002). It is also important to stress that most fungal infections 
are located in the tissue, such as the lung, kidney, liver, and spleen. In these organs, AMB levels 
given as L-AMB are maintained above the MIC for many species for at least 1 week and longer, 
depending of the tissue (Adler-More and Proffitt, 2003; Smith et al., 2007).  
 
Spectrum of activity  
Amphotericin B exhibits a broad spectrum of activity. It is active against most Candida 
species and Cryptococcus neoformans as well as many molds, including Aspergillus spp., 
Fusarium spp. and Zygomycetes (Chandrasekar, 2011). Most C. albicans and C. parapsilosis 
might be considered to be fully susceptible to AMB, although there have been occasional reports 
of resistant clinical isolates (Ellis, 2002). While C. tropicalis and C. guilliermondii are also 
considered susceptible, can C. glabrata and C. krusei exhibit decreased susceptibility to AMB 
(Ellis, 2002; Pfaller and Diekema, 2007). Despite some strains of C. lusitaniae have been reported 
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to be resistant to AMB, most strains appear to be susceptible when tested in laboratory. 
Regarding the molds, most species of Aspergillus are susceptible to AMB; however, a reduced 
susceptibility to amphotericin B has been described among isolates of A. ﬂavus and A. terreus 
(Barchiesi et al., 2013; Gregg and Kauffman, 2015).  
 
Development of resistance 
After more than 50 years of use as monotherapy, the acquisition of amphotericin B 
resistance remains extremely rare, contrary to azoles and echinocandin drugs. Resistance to 
AMB is an uncommon phenomenon in Candida (1-3%, particularly in C. lusitaniae), and 
Aspergillus, although a considerable proportion of A. terreus and A. flavus has higher MIC values 
(McClenny NB et al., 2002; Pfaller and Diekema, 2007; Cuenca-Estrella, 2014, Gonçalves et al., 
2016). Because the lack of clinical strains with resistance to amphotericin B, few studies 
addressing the molecular resistance mechanisms have been reported. It has been published that 
resistance to amphotericin B is associated with mutants with low levels of ergosterol and/or prior 
exposure to azole antifungals, and disturbance of the levels and composition of the phospholipids 
in the membrane. Some of these changes have been associated with mutations in genes involved 
in ergosterol biosynthesis ERG2, ERG3, ERG5, ERG6, and ERG11 (Vincent et al., 2013). 
Furthermore, it was described that perturbations in ergosterol biosynthesis can lead to general 
increases in the accumulation of diverse small molecules involved in stress response. One of the 
most powerful and highly conserved adaptation mechanisms comprises the heat shock proteins 
(Hsps). Hsps function as molecular chaperones, which repair and adapt to cell damage caused 
by aggregated proteins and ensure proper folding of newly synthesized proteins (Blatzer et al., 
2015). It is already described the critical role of Hsp90 in the evolution of AMB resistance in 
Candida and Aspergillus (Vincent et al., 2013; Blatzer et al., 2015). Hsp90 also promotes the 
maturation of a diverse array of metastable signal transduction proteins (known as Hsp90 clients) 
that function in many stress response pathways. Normally, these client proteins are nonessential 
stress responses; however, they become essential in AMB-resistant strains. Vincent et al., has 
demonstrated that Hsp clients, calcineurin and protein kinase C pathways are required to tolerate 
the stresses imposed by resistance mutations. In turn, the MAP-Kinase Hog1 only is required to 
tolerate the stress induced by AMB exposure (Vincent et al., 2013; Cohen, 2014). In addition, the 
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polyenes induce oxidative stress in fungal cells that lead to development of robust stress 
responses to counteract the antimicrobial action. It was described that the less susceptible 
isolates can have higher levels of antioxidative enzymes and/or alterations in the production of 
free radicals (Cohen, 2014; Cuenca-Estrella, 2014; Gonçalves et al., 2016). According to Vincent 
et al., every mutation that can confer robust AMB resistance came at great cost to the pathogen, 
and therefore these phenotypes do not become prevalent in the clinic (Vincent et al., 2013). 
Therefore, its expression at a clinical level may ultimately be somewhat reduced and such strains 
are not prone to thrive and colonize the human host. 
 
Antifungal susceptibility testing 
In recent years we have seen major advances in susceptibility testing for fungi. The need 
for reproducible and clinically relevant antifungal susceptibility testing has been encouraged by 
the increasing number of IFIs, the expanding use of antifungal agents, and the development of 
antifungal resistance (Ellis, 2002; Pfaller and Diekema, 2012). There are two internationally 
recognized standard methods for the performance of antifungal susceptibility testing of yeast and 
molds, both using broth microdilution (BMD): the Clinical and Laboratory Standards Institute 
(CLSI) (CLSI 2008a,b, 2012) and the European Committee on Antimicrobial Susceptibility Testing 
(EUCAST) (EUCAST 2017a,b). Although the CLSI method has provided reliable and reproducible 
results, it generates a restricted range of amphotericin B minimal inhibitory concentrations (MICs), 
precluding reliable discrimination between susceptible and resistant isolates of Candida species 
and preventing the development of clinical interpretive breakpoints (CBPs) for AMB in vitro testing 
(Park et al., 2006). Analyses of both clinical trial data and clinical and microbiological data from 
population-based surveillance studies for Candida species also have failed to establish any 
clinical correlation between amphotericin B MICs, as determined by CLSI BMD and clinical 
outcome (Pfaller and Diekema, 2012). While for the CLSI protocol there are no CBPs defined for 
the Candida species, the epidemiological cutoff value (ECV) for AMB is 2 mg/L for all species. 
Whenever the MIC value is ≤ 2 mg/L the strain is wild-type (WT, without mutational or acquired 
resistance mechanisms); whenever the MIC value is > 2 mg/L the strain is non-WT, having 
mutational or acquired resistance mechanisms (Pfaller and Diekema, 2012). Regarding 
Aspergillus spp., the ECVs for the CLSI method are 2 mg/L for A. fumigatus and A. flavus, and 4 
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mg/L for A. terreus; whereas the CBP is 1 mg/L for all Aspergillus species (Elefanti et al., 2014). 
The EUCAST method has already determined AMB clinical breakpoints for Candida spp.; C. 
albicans, C. glabrata, C. krusei, C. parapsilosis and C. tropicalis are S whenever MIC ≤ 1 mg/L 
and R when MIC > 1 mg/L (Lass-Florl et al., 2011). For Aspergillus spp., the ECVs are 1 mg/L in 
case of A. fumigatus and 4 mg/L for A. flavus and A. terreus; in turn, the susceptible breakpoint 
is 1 mg/L for all species (Arendrup et al., 2012; Elefanti et al., 2014). In addition to lack of 
consensus between CLSI and EUCAST methods, its essential agreement is often poor for some 
species of Candida, namely C. albicans and C. glabrata (Pfaller et al., 2014). The standardization 
of reference methods by CLSI and EUCAST has led to the development of several automated or 
semiautomated commercial systems like the Sensitrite YeastOne, Etest, and Vitek 2. The first is 
a broth microdilution method that determines the susceptibility profile of yeast and filamentous 
fungi; the Etest is a susceptibility method using a strip with a predefined concentration gradient 
of the antimicrobial agent that provides the MIC value, which is difficult to interpret for both yeast 
and molds; Vitek 2 is an automated commercial method that allows both yeast identification and 
MIC determination (Ellis, 2002; Canton et al., 2009; Cuenca-Estrella et al., 2010). Since they all 
dependent of cell growth, all these methods are time consuming, and often provide contradictory 
results. Recently, flow cytometry (FC) has demonstrated to be a valuable tool for evaluation of 
antifungal susceptibility testing in yeasts, since it can be used to detect different cellular 
physiological status induced by the antifungal action by means the use of appropriate fluorescent 
dyes (Chaturvedi et al., 2004; Czechowska et al., 2008; Pina-Vaz and Rodrigues, 2010). FC 
susceptibility testing to azoles, amphotericin B, and echinocandins has already been described 
(Kirk et al., 1997; Ramani et al., 1997; Pina-Vaz et al., 2001a, 2001b and 2010; Rudensky et al., 
2005). This new methodology has the advantage of providing timely results (4h versus 24 or 48h 
of available methods). Several authors have considered that routine antifungal susceptibility 
testing can serve as an adjunct in the treatment of IFIs (Collins et al., 2007; Perkins et al., 2005); 
however, susceptibility testing is not always performed routinely because the available methods 
are cumbersome and the time to results is high, what means that patients are often treated 
empirically. In addition, the lack of well-established clinical breakpoints for AMB and the 
consequently poor correlation with the clinical outcome may impair the clinical success.   
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Clinical outcome 
Despite the confirmed in vitro susceptibility (0.125 to 1 mg/L), in vivo response to 
liposomal amphotericin B is somewhat reduced and an unfavorable outcome is reported in about 
40% of the treated patients (Ullmann et al., 2006; Moen et al., 2009). The exact reasons for such 
dismal response remain unclear. Some authors do not associate this response failure with target 
modification as it happens with other antifungal drugs, but with inappropriate concentration of 
amphotericin B at the infection site (Liao et al., 2003; Shapiro et al., 2011; Vincent et al., 2013). 
Although the underlying diseases, immunosuppression, concomitant therapies, toxicity, 
and timing of antifungal therapy affect the mortality of these infections, pathogen susceptibility 
and AMB plasma and tissue concentrations also represent crucial contributing factors for the 
success of therapy, that deserve future elucidation in order to obtain an improved clinical 
response (Elefanti et al., 2014). 
 
COMBINATION THERAPY: THE EFFECT OF AMPHOTERICIN B IN ASSOCIATION 
WITH OTHER COMPOUNDS 
 
Monotherapy regimens are often ineffective against IFIs, resulting in an unfavorable outcome. 
Combination therapy may thus represent a beneficial therapeutic option, although there are few 
scientific studies showing the potential advantages of such approach.  
 
i. With antifungal compounds 
The association of AMB with anidulafungin was described as having a synergic interaction 
against Candida spp. (Rosato et al., 2012; Valentin et al., 2012). Several studies have also 
described that the combination of AMB with caspofungin, another echinocandin, resulted in a 
synergistic effect against Aspergillus spp., Fusarium spp. and C. glabrata (Arikan et al., 2002; 
Kiraz et al., 2009; Liu et al., 2012). Nishi et al., have described that the combination of micafungin 
and AMB also had a benefic effect against C. glabrata (Nishi et al., 2009). Likewise, the 
combination of 5-fluorocytosine and AMB has showed to improve the antifungal effect upon 
Cryptococcus neoformans, even in flucytosine-resistant isolates (Schwarz et al., 2007). Recently, 
Gazzoni et al., have described that voriconazole in association with AMB results in a synergistic 
interaction against C. neoformans (Gazzoni et al., 2012).  
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Although the association of antifungal drugs with different mechanisms of action seems to be 
benefic for the treatment of IFIs, in the cited studies, the effect of drug association was often 
dependent on the tested isolate. It should be stressed that the methods for evaluation the in vitro 
drugs interaction are cumbersome and difficult to interpret, and sometimes provide contradictory 
results.  
 
ii. With antibacterial compounds 
Since 1970s synergistic effects between tetracycline (TET) and AMB against C. albicans and 
other pathogenic fungi were described (Oliver et al., 2008). Tetracycline has a direct effect upon 
the mitochondrial function in fungi. According to the authors, the inhibition of the mitochondria 
function in fungal cells by TET, impairs the sterol metabolism, resulting in lower sterol levels. 
Thus, cells exposed to TET are more susceptible to AMB due to a higher ratio AMB/ergosterol at 
the cell surface (Oliver et al., 2008).  Clancy and Nguyen, have showed that the combination of 
AMB and azithromycin (AZM) improved the antifungal effect, reducing AMB minimal inhibitory 
concentration in Fusarium spp. (Clancy and Nguyen, 1998). Azithromycin acts in bacterial cells 
by inhibiting protein synthesis. While the mechanism of synergism between these two compounds 
remains unclear, it has been postulated that AMB, by damaging the fungal cell membrane, may 
facilitate the entrance of AZM into the cells; once inside the cells AZM might act by inhibiting 
fungal protein synthesis (Clancy and Nguyen, 1998). Several studies have demonstrated that the 
combination of AMB with rifampicin (RIF) results in a synergistic effect (Ansehn et al., 1976; 
Srimuang et al., 2000; El-Azizi, 2007). This effect could be related to the fact that AMB binds to 
the sterols in the fungal cell membrane, thus increasing the antibacterial permeability and 
facilitating the RIF action on RNA synthesis (Azevedo et al., 2015). A recent study has also 
described synergistic effects between AMB and clarithromycin (CLR) (Del Pozo et al., 2011). 
Fungal cell membrane damaged by AMB action, may allow the entrance of CLR, inhibiting the 
protein synthesis (Azevedo et al., 2015).  Recently, Zeidler et al., have reported the synergism of 
colistin with AMB (Zeidler et al., 2013). Attending to such studies, the association between 
antibacterial agents and AMB could represent a very interesting therapeutic approach.   
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ABSTRACT 
 
In vitro resistance to amphotericin B is an extremely rare event among pathogenic yeasts. 
However, in vivo response is sometimes reduced, resulting in an unfavorable outcome. Such 
adverse outcomes might be related to subfungicidal plasma concentrations. We aimed to clarify 
the mechanisms of liposomal amphotericin B (L-AMB, AmBisome)-induced lesions and the 
mechanisms responsible for yeast cell recovery following exposure at plasma concentrations. 
The physiological statuses developing following exposure to L-AMB at simulated plasma 
concentrations (20 to 0.1 mg/L) and at a constant concentration (3 mg/L) were assessed in a 24 
h time course assay. Time-kill experiments were also carried out under the same L-AMB 
treatment conditions. 
Our results suggest that yeast cells develop compensatory responses related to 
membrane polarization, metabolic activity, and reactive oxygen species (ROS) production after 
exposure to high plasma concentrations (20 to 5 mg/L) during the first 6 h; in the remaining 18 h, 
when exposed to lower concentrations, cells reveal almost full recovery with no evidence of 
fungicidal activity. In contrast, whenever cells are exposed to a constant concentration above the 
MIC, despite initially exhibiting compensatory stress responses, soon afterwards they exhibit 
membrane depolarization, a decrease of metabolic activity, increasing ROS production, and 
lastly, programmed cell death and necrosis, thus succumbing to L-AMB fungicidal effect. 
This study may represent a step forward in the support of L-AMB use for clinical treatment 
of invasive fungal infections, since it demonstrates the importance of maintaining the levels of L-
AMB above the MIC in the plasma and the tissues to ensure it produces its fungicidal effects.    
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BACKGROUND 
 
The understanding of how fungal organisms respond to antimicrobial therapy is a relevant 
question both in terms of evolutionary biology and for treatment of invasive fungal infections. 
During recent decades, fungi have emerged as major human pathogens; Candida albicans 
represents the fourth most common agent of all hospital-acquired infections (Pfaller and Diekema, 
2007).  
Despite over 50 years of use as monotherapy, amphotericin B (AMB) still represents an 
important therapeutic alternative for the treatment of systemic fungal infections, particularly when 
infection persists despite treatment with alternative drugs (Mora-Duarte et al., 2002). 
Amphotericin B belongs to polyene drug class and exhibits a broad-spectrum fungicidal activity. 
For decades, the prevailing mechanism of action has been that AMB primarily binds to ergosterol, 
inserts into the cytoplasmic membrane, and forms pore-like structures; the result is osmotic 
instability, loss of membrane integrity, metabolic disruption, and ultimately cell death (Zhang et 
al., 2002; Gray et al., 2012). Recently, Anderson et al. proposed a new mechanism of action of 
AMB. Accordingly, amphotericin exists primarily in extramembranous aggregates that kill yeast 
cells by extracting ergosterol from the plasma membrane. Consequently, membrane ergosterol 
depletion will interfere not only with cell membrane integrity but also with other cellular processes 
which highly depend on membrane ergosterol (Anderson et al., 2014). 
The development of genetic resistance to AMB among Candida species remains 
extremely rare, in contrast to what is observed with other drugs in the triazole or echinocandin 
classes (Martel et al., 2010; Walker et al., 2010). However, in spite of the observed high in vitro 
susceptibility (0.125 to 1 mg/L), the in vivo response to AMB is somewhat reduced in about 40% 
of treated patients (Ito and Hooshmand-Rad, 2005; Park et al., 2006; Larsen et al., 2011). The 
exact reasons for this lower-than-expected response still remain unclear. Some authors do not 
associate response failure with target modification, as has been observed with other antifungal 
drugs (Shapiro et al., 2011), but with inappropriate concentrations of AMB at the infection site 
(Liao et al., 2003). In accordance with this hypothesis, cells exposed to amphotericin B may 
exhibit different physiological conditions which are related to drug concentration and exposure 
time (Liao et al., 2003). In addition, studies of yeast apoptosis have revealed the occurrence of a 
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programmed cell death or a cellular necrotic response depending on the AMB concentration 
(Phillips et al., 2003; Al-Dhaheri and Douglas, 2010).   
Considering the clinical relevance of liposomal amphotericin B (L-AMB) and based on 
plasma levels described previously (Walsh et al., 1998), this study aims to explore yeast survival 
mechanisms in response to L-AMB in order to identify different physiological conditions following 
exposure to decreasing concentrations in a time course assay. In addition, we intend to determine 
whether cell survival following exposure to L-AMB is a common phenomenon among different 
yeast species, some of which are relevant clinical pathogens. 
Our results provide novel insights regarding mechanisms by which yeast cells can escape 
to L-AMB fungicidal action depending upon the time of exposure and the concentration of the 
drug. 
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MATERIAL AND METHODS 
 
Yeast strains and growth conditions 
A broad range of pathogenic and nonpathogenic yeasts were grown in yeast extract-
peptone-dextrose (YPD) liquid medium (1% yeast extract, 2% peptone, 2% dextrose; Formedium, 
Norfolk, United Kingdom) at 35 °C with shaking (150 rpm) until exponential growth phase (details 
are presented in Table 1) (Costa-de-Oliveira et al., 2013). All of the strains were subjected to 
antifungal susceptibility testing, cell viability assays, and membrane potential evaluation. For 
membrane integrity, metabolic activity, reactive oxygen species (ROS) production, and apoptotic 
assays, only Saccharomyces cerevisiae BY4741 was used as model organism. Prior to 
experiments, yeasts were subcultured twice in YPD agar to ensure the purity of cultures. 
 
Liposomal amphotericin B susceptibility 
The MIC of L-AMB (provided by Gilead Sciences, Inc, San Dimas, California) was 
determined according to the M27-A3 protocol and M27-S3 supplement of the Clinical and 
Laboratory Standards Institute (CLSI) (Wayne PA, a2008, b2012). MIC values were determined 
after 24 and 48 h of incubation with L-AMB; MIC was the lowest concentration that prevented any 
discernible growth.  Due to a lack of established clinical breakpoints for AMB, the Candida isolates 
were considered “wild-type” (wt) whenever MIC ≤ 2 mg/L and “non-wild-type” (nwt) when MIC > 
2 mg/L, according to the epidemiological cutoff values (ECVs) proposed by Pfaller and Diekema. 
For non-Candida genera, it is only displayed the MIC value, since amphotericin B ECVs and 
clinical breakpoints remain yet undefined (Pfaller and Diekema, 2012). C. albicans ATCC 90028 
reference type strain was used as recommended by the CLSI protocol. 
 
Evaluation of cell viability 
Yeast suspensions (106 yeast cells/mL) were exposed to L-AMB, in accordance with the 
plasma levels established by Walsh et al. (Walsh et al., 1998). Briefly, cell suspensions were 
treated with L-AMB 10 mg/L for 30 min; afterwards, cells were harvested by centrifugation at 
1,610 x g for 10 min at room temperature (Universal 320R; Hettich). The same cells then were 
resuspended in fresh culture medium and exposed sequentially to serial concentrations of L-AMB: 
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20 mg/L (for 30 min), 10 mg/L (for 2 h), 5 mg/L (for 3 h), 1 mg/L (for 6 h) and 0.1 mg/L (until 24 h) 
(detailed in Figure 1A). Another cell suspension was treated with 3 mg/L L-AMB for 24 h. During 
that period at 1, 3, 6 and 12 h of treatment, those cells were harvested (Universal 320R; Hettich) 
and resuspended in fresh medium containing L-AMB 3 mg/L, similar to the protocol developed for 
the cells exposed to various dosages of L-AMB (plasma conditions). Following 1, 3, 6 and 24 h 
from start of incubation, the number of viable cells was determined by plating on YPD agar and 
incubating at 35°C for 24 h; the number of CFUs was determined and compared with plate control 
(not exposed to L-AMB). Before being plated, cells were washed and resuspended in fresh 
medium in order to prevent antifungal carryover.  
 
Functional characterization of liposomal amphotericin B-induced action 
The physiological status of yeast cells which developed following L-AMB exposure to 
decreasing concentrations or a constant concentration of L-AMB in a time course assay were 
assessed by flow cytometry. A cell suspension corresponding to 106 yeast cells/mL was used in 
all assays described below. Yeast cells were incubated with various concentrations of L-AMB, in 
accordance with the scheme previously proposed (Figure 1A). At 1, 3, 6 and 24 h, aliquots were 
collected and tested; all cytometric evaluations were performed in a standard FACSCalibur 
cytometer (BD Biosciences, Sydney, Australia) equipped with 3 photomultipliers (PMTs), 
standard filters, and a 15-mW 488-nm Argon laser using CellQuest Pro software (version 4.0.2). 
All trials were performed in triplicate.  
 
Assessment of membrane integrity   
Cell membrane integrity was assessed with propidium iodide (PI; Sigma-Aldrich, Munich, 
Germany) staining. After antifungal treatment, yeast cells were stained with 1 mg/L of PI for 30 
min at 35°C at 150 rpm in the dark (Pina-Vaz et al., 2005). The fluorescence intensity (FI) was 
measured at FL3 (630 nm). The amount of injured cells in each sample was defined as the 
percentage of PI-positive cells. 
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Assessment of membrane potential 
The effect of L-AMB exposure on cell membrane potential was evaluated using Bis-(1,3-
Dibutylbarbituric Acid) Trimethine Oxonol [DiBAC4(3): Sigma-Aldrich, Munich, Germany] as 
described by Teixeira-Santos et al. (Teixeira-Santos et al., 2012). After L-AMB treatment, cells 
were incubated for 15 min in the dark at 35 °C, at 150 rpm, with 0.5 mg/L of DiBAC4(3) . The FI 
was registered at FL1 (530 nm). 
 
Assessment of metabolic activity 
Metabolic changes induced by L-AMB in S. cerevisiae were evaluated using 5-
Carboxyfluorescein diacetate (5-CFDA; Sigma-Aldrich, Munich, Germany), at 10 µM final 
concentration. Antifungal-treated cell suspensions were stained with 5-CFDA and incubated for 
45 min, at 35 °C, at 150 rpm in the dark (Liao et al., 2003). The mean intensity of fluorescence 
(MIF) was registered at FL1 (530 nm). 
 
Assessment of endogenous ROS production 
ROS production was assessed as previously reported (Yan et al., 2009). In brief, the cell 
suspension was incubated with 20 mg/L of 2,7-dichlorofluorescin diacetate (DCFH-DA; Sigma-
Aldrich, Munich, Germany) for 30 min at 35°C at 150 rpm. Yeast cells were washed (2,655 x g for 
5 min at room temperature; 5417R, Eppendorf) and resuspended PBS (Sigma-Aldrich, Munich, 
Germany); afterwards, cells were treated as described above. As control, cells were treated with 
H2O2 0.4 mM (PanReac, Castellar del Valles, Spain). The FI was determined at FL1 (530 nm). 
ROS production was calculated by subtracting the FI value of cells treated with simple antifungal 
agent from that of cells treated with both antifungal agent and DCFH-DA.  
 
TUNEL assay 
DNA strand splitting was demonstrated by terminal deoxynucleotidyl transferase-
mediated dUTP-biotin nick end labeling (TUNEL) with the in situ cell death detection kit, 
fluorescein, from Roche (Mannheim, Germany). Yeast cells were fixed with 3.7% (vol/vol) 
formaldehyde (Applichem, Darmstadt, Germany) for 30 min at room temperature and washed 
thrice with PBS (2,655 x g for 5 min at room temperature; 5417R, Eppendorf). Afterwards, cell 
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walls were digested with 24 mg/L of lyticase (Sigma-Aldrich, Munich, Germany) at 37°C for 60 
min. Cells were rinsed with PBS, incubated in permeabilization solution (0.1% [vol/vol] Triton X-
100 and 0.1% (wt/wt) sodium citrate) for 2 min on ice, and rinsed twice with PBS (5417R, 
Eppendorf). For a positive control, cells were treated with DNase I enzyme (Roche, Mannheim, 
Germany) for 10 min and then washed twice in PBS (5417R, Eppendorf). Yeast cells 
subsequently were incubated with 15 µL of TUNEL reaction mixture, for 60 min at 37°C and then 
washed twice in PBS (5417R, Eppendorf). Finally, cell suspensions were submitted to flow 
cytometric analysis, and the percentage of apoptotic cells was determined at FL1 (530 nm).  
Simultaneously, 10 µL of the treated cell suspension was placed in a microscope slide, 
and the protocol for 4′,6-diamidino-2-phenylindole (DAPI; Roche, Mannheim, Germany) nuclear 
staining was carried out as previously described, using 1 mg/L of DAPI (Almeida et al., 2007), for 
further analysis under fluorescence microscopy with a Carl Zeiss Axiovert inverted microscope 
and laser wavelengths of 405 nm (DAPI) and 488 nm (TUNEL). 
 
Statistical analysis  
Results are presented as mean value and the respective standard deviations. A 
comparison of results was performed using paired-samples Student’s t test. P < 0.05 was 
considered significant. For calculations of all measures, the SPSS program (version 19.0) was 
used. 
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RESULTS 
 
Liposomal amphotericin B effect on cell viability 
Our primary goal in this study was to determine the effect of therapeutic plasma 
concentrations of L-AMB upon cell viability. We focused on L-AMB effects within the first 24 hours 
of exposure, a time period corresponding to the first drug infusion. The effect of L-AMB on yeast 
cells was evaluated by colony forming units count following incubation with decreasing 
concentrations of L-AMB (Figure 1B). As detailed in Figure 1B, a slight reduction of viability was 
observed for up to 6 h of exposure; however, after 6 h of exposure to decreasing concentrations, 
cells recovered their replication ability with this effect being most marked after 24 h of exposure 
(106 to 109 cells/mL). Conversely, in the case of cells exposed to L-AMB 3 mg/L for 24 h, a growth 
reduction was consistently registered throughout the 24 h period, and the cells were unable to 
replicate. At 24 h, a significant difference between both experimental conditions was registered 
(p < 0.001).  
 
Figure 1 - Effect of liposomal amphotericin B on S. cerevisiae BY4741 and C. albicans 596. (A) Study design 
scheme. (a) Plasma concentration-time curve obtained after a first infusion of L-AMB at 3 mg/L. (b) The scheme proposed 
in accordance with L-AMB plasma levels described by Walsh et al. (Walsh et al., 1998); (c) Dashed line represents the 
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treatment with a constant concentration of 3 mg/L L-AMB during 24 hours. (B) Viability assessment by CFU enumeration 
of S. cerevisiae BY4741 and C. albicans 596 cells exposed to treatment conditions (b) and (c). Data at respective time 
points are given as mean ± standard deviations.  An asterisk indicates significant differences between the two treatment 
conditions. 
 
Overall, the killing kinetics were similar among all species studied (Table 1). S. cerevisiae 
BY4741 and C. albicans 596 are representative examples (Figure 1B). When comparing such 
results with the assessment of cell viability with PI (Figure 2A), we observed some discrepancies. 
While after 1, 3 and 6 h of incubation with L-AMB under both drug treatment conditions there was 
a reduction of colony forming units per milliliter, the cells were not permeable to PI. Only after 24 
h was any PI uptake observed, but it was seen in only about 50% of the cells treated with L-AMB 
3 mg/L. 
 
Liposomal amphotericin B-induced alterations on membrane potential 
To assess the effect of L-AMB on the cytoplasmic membrane potential of yeast cells, we 
used DiBAC4(3) staining. DiBAC4(3) enters only depolarized cells, where it binds reversibly to 
intracellular components, resulting in an increased fluorescent signal. The results obtained 
regarding membrane depolarization of S. cerevisiae BY4741 are depicted in Figure 2B. Viable 
nontreated cells stained with DiBAC4(3) exhibited a small percentage of depolarized cells (≈ 5%), 
which remained constant over time. Cells treated with L-AMB plasma concentrations displayed 
an increase of depolarized cells (DC) up to 6h of incubation; the percentage of DC at 1, 3 and 6 
h of incubation was 13,01%, 20,13% and 45,83%, respectively. Interestingly, after 24 h of 
incubation, membrane yeast cells seemed to repolarize, corresponding to a DC final value of 
19,67%. Conversely, treatment of yeast cells with L-AMB 3 mg/L resulted in a time-dependent 
increase of depolarized cells. Figure 2B shows that following 24 h of incubation, cells treated with 
3 mg/L L-AMB displayed higher membrane depolarization than cells treated with plasma 
concentrations; the percentage of depolarized cells at this time point was 80,45%.  
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Figure 2 - Effect of liposomal amphotericin B on S. cerevisiae BY4741 physiological parameters.  (A)  Cell 
membrane integrity was assessed with propidium iodide (PI). (B)  Cell membrane potential was evaluated using 
DiBAC4(3). (C) Metabolic activity was determined by 5-CFDA staining. (D) Endogenous reactive oxygen species (ROS) 
production as determined by DCFH-DA staining. An asterisk indicates significant differences (P < 0.05) between the two 
treatment conditions. 
 
To evaluate whether this mechanism of cell salvage is conserved in the presence of 
decreasing concentrations of L-AMB during a 24 h period among distinct yeasts, a broad range 
of yeast species with different phylogenetic relationships (see Table 1) were assessed by flow 
cytometry regarding the respective cell membrane potential. The species studied showed 
different susceptibility profiles to L-AMB with all wild-type Candida strains (MIC, ≤ 2 mg/L), except 
C. krusei with a MIC of 8 mg/L. Non-Candida yeast genera also showed MIC values of < 2 mg/L. 
Regardless of the susceptibility profile, all species studied revealed depolarization of cell 
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membrane after 6 h of incubation with L-AMB plasma concentrations, followed by repolarization 
of the cell membrane by 24 h (Table 1). However, cells treated with 3 mg/L L-AMB exhibited a 
time-dependent increase of membrane depolarization (data not shown).  
 
Table 1 – Yeast strains used in this study. Liposomal amphotericin B susceptibility test results and membrane potential 
of yeast cells treated with L-AMB plasma concentrations after 3, 6 and 24 h, expressed as percentage of depolarized 
cells. 
ID Species Source 
MIC  
(mg/L) 
% of depolarized cells 
3 h 6 h 24 h 
ATCC 90028 Candida albicans American Type Culture Collection 0.5 61.21 77.42 26.66 
596 Candida albicans Clinical isolate 0.5 33.62 40.16 21.72 
590 Candida glabrata Clinical isolate 1 28.19 37.51 20.04 
597 Candida parapsilosis Clinical isolate 0.5 34.62 45.98 9.57 
120 Candida krusei  Clinical isolate 8 31.08 43.29 19.81 
514 Candida tropicalis Clinical isolate 1 48.65 77.92 21.54 
479 Candida dubliniensis Clinical isolate 0.06 21.64 36.73 25.57 
520 Candida lusitaniae Clinical isolate 0.25 30.18 33.21 22.94 
D1 Cryptococcus neoformans Clinical isolate 0.5 28.14 35.79 19.31 
BY4741 Saccharomyces cerevisiae American Type Culture Collectiona 0.5 20.13 45.83 19.67 
PYCC 6480 Debaryomyces hansenii Portuguese Yeast Culture Collectiona 1 43.78 89.90 30.47 
PYCC 4166 Kluveromyces lactis Portuguese Yeast Culture Collectiona 0.06 27.89 38.89 5.63 
CBS 732 Zygosaccharomyces rouxii CBS-KNAW Fungal Biodiversity Centera 0.06 14.85 34.71 12.38 
akindly provided by Prof. Catarina Prista, Instituto Superior de Agronomia, Lisboa, Portugal.  
 
Metabolic alterations triggered by L-AMB exposure 
To assess metabolic effects of L-AMB on S. cerevisiae cells, we performed 5-CFDA 
staining. 5-CFDA is a cell-permeant esterase substrate; it measures both enzymatic activity and 
cell membrane integrity. The results obtained for MIF displayed by cells stained with 5-CFDA are 
detailed on Figure 2C. The MIF displayed by viable cells not treated with L-AMB following 1 h of 
treatment was 820.05; it increased after 6 h of incubation (MIF = 1,127.35) and remained constant 
up to 24 h. After 1 h of incubation, yeast cells treated with plasma concentrations of L-AMB 
displayed a MIF slightly higher than viable cells (901.01). However, following 3 and 6 h, the MIF 
decreased to values of 721.33 and 549.78 respectively; afterwards, the MIF remained constant 
until 24 h of treatment. When yeast cells were treated with 3 mg/L L-AMB over time, the MIF 
increased after 1 h of incubation (MIF = 923.54), indicating that the cells were metabolically active. 
However, after 3 h of incubation, the MIF decreased over time; at 24 h the MIF was 327.49. This 
event may be related to a lower enzyme activity or cell membrane injury. 
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Induction of endogenous ROS production by L-AMB 
Reactive oxygen species production was assessed by DCFH-DA staining. DCFH-DA is 
oxidized to highly fluorescent 2’,7’- dichlorodihydrofluorescein (DCF) by ROS. Exposure to L-AMB 
plasma concentrations resulted in reduced ROS formation in S. cerevisiae cells (≈ 18%) (Figure 
2D). In contrast, prolonged and constant exposure to 3 mg/L L-AMB resulted in high formation of 
ROS (p <0.001); after 6 h of incubation, a significant increase of the number of fluorescent cells 
(reaching 100%) was registered. This assay reveals that 3 mg/L L-AMB leads to intracellular 
accumulation of ROS, which is associated with oxidative damage and possibly is involved in 
induced programmed cell death. 
 
DNA damage and nuclear fragmentation  
DNA fragmentation was measured by TUNEL assay. The percentage of S. cerevisiae 
cells that exhibited TUNEL-positive nuclei after exposure to plasma concentrations of L-AMB for 
3 and 6 h was about 20% (Figure 3). There were significant differences between cells exposed 
to L-AMB plasma concentrations and to 3 mg/L L-AMB (p <0.001); following exposure to L-AMB 
at a constant 3 mg/L concentration, TUNEL-positive cells increased over time, indicating 
apoptotic-like DNA-fragmentation; after 24 h of incubation with 3 mg/L of L-AMB, 60.8% of yeast 
cells exhibited TUNEL-positive nuclei, twice the proportion of TUNEL-positive cells following 
exposure to L-AMB plasma concentrations (Figure 3A, 3B). During apoptosis, S. cerevisiae cells 
exposed to L-AMB exhibited evidence of nuclear fragmentation associated with DNA damage 
(Figure 3C), including irregular shaped DNA, as previously described (Wu et al., 2010). 
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Figure 3 - TUNEL staining of S. cerevisiae BY4741 cells exposed to liposomal amphotericin B. (A) Fluorescence 
microscopy imaging showing TUNEL-positive cells after treatment with L-AMB plasma concentrations (a) and with 3 mg/L 
(b) after 3, 6 and 24 h.  (B) Percentage of cells exhibiting damaged DNA (i.e., cells positive by TUNEL) after treatment 
with L-AMB, as assessed by flow cytometry. An asterisk indicates significant differences (P < 0.05) between the two 
treatment conditions. (C) Nuclear fragmentation as shown by DAPI staining. Fluorescence microscopy imaging with (a) 
and without (b) DAPI filter. S. cerevisiae cells exposed to L-AMB exhibit an irregular shape and fragmented DNA, two 
findings in accordance with DNA damage during apoptosis.  
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DISCUSSION 
 
Our study clearly demonstrated that exposure to L-AMB plasma concentrations induces 
compensatory responses at distinct levels, like replicative ability, membrane potential, metabolic 
activity, endogenous ROS production, and DNA damage. In the treatment regimen with plasma 
concentrations, yeast cells are exposed to high concentrations of L-AMB (5-20 mg/L) over a short 
time period (6 h), which can trigger a stress response. Consequently, the yeast cells initially 
compensate by upregulating their physiological responses to minimize this stress; afterwards, 
over the remaining 18 h they are exposed to a much lower L-AMB concentration, which allows its 
recovery.  This may explain why the yeast cells exposed to the simulated plasma concentrations 
are less L-AMB susceptible. Accordingly, no evidence of fungicidal activity was found, which may 
be responsible for fungal infection persistence in the blood of these patients. Conversely, following 
constant exposure to 3 mg/L, cells develop compensatory mechanisms for survival initially; 
however, as the concentration is kept constant for 24 h, the cells succumb to the drug effects. In 
addition, in interpreting this data, one also has to consider the fact that most fungal infections 
localize in the tissues, such as the lungs, kidneys, liver and spleen. In these tissues, 
concentrations of L-AMB reach well above the MIC and are maintained at these levels for at least 
1 week and longer depending upon the tissues (Adler-Moore and Proffitt, 2003; Smith et al., 
2007).  
An important challenge for cell physiology and microorganism survival is a successful, 
balanced growth when confronted with environmental imbalances. A variety of cellular processes 
and physiological changes have to be coordinated to allow yeast cells to reproduce, grow, and 
respond to environmental stresses (Brauer et al., 2008). We demonstrated that yeast cells use 
distinct time-programmed mechanisms to respond to L-AMB-induced stress. When yeast cells 
were exposed initially to high concentrations of L-AMB (5 to 20 mg/L) during the first 6 h, followed 
by much lower levels of drug, closer to their MIC (simulated plasma concentrations), the loss of 
replication competency seems to be a relatively early event that could be easily overcome, 
provided that the yeast then were exposed for longer periods of time to drug concentrations at or 
below their MICs (Figure 1B).  Previous studies have shown that some yeast cells exposed to 
amphotericin B demonstrate a capacity for resuscitation, although they are unable to replicate 
New insights regarding yeast survival following exposure to L-AMB 
 
 
41 
 
(Liao et al., 1999 and 2003). It is notable that increasing and then decreasing L-AMB 
concentrations rapidly evoke compensatory responses by yeast cells, including the recovery of 
replication ability. Interestingly, such cells appear to exhibit an intact cell membrane, as shown by 
PI staining (only about 5% of cells are PI positive after 24 h) (Figure 2A). Conversely, yeast cells 
constantly exposed to 3 mg/L L-AMB lose their viability, as confirmed by CFU determination, also 
with clear evidence of cell membrane injury (50% of cells PI positive at 24h).  
 Regarding membrane potential, the phenomenon of cell salvage was found to be 
conserved among different yeasts (pathogenic and nonpathogenic) with different phylogenetic 
relationships and antifungal susceptibility profiles, suggesting that this recovery is related to 
insufficient L-AMB exposure.  An essential aspect of environmental adaptation is the equilibrium 
of ion concentration, which determines cell membrane potential (Ke et al., 2013). It is well known 
that amphotericin B increases fungal cell membrane permeability to ions (Milhaud et al., 2002). 
Yeast cells initially exposed to high L-AMB concentrations exhibited evidence of plasma 
membrane depolarization soon after 1, 3 and 6 h of incubation, as shown by DiBAC4(3) staining; 
however, in such cells membrane potential was restored afterwards during the time that the cells 
were exposed to levels of drug close to or below their MICs (Figure 2B). Our results suggest that 
with initial exposure to high L-AMB levels, there is a cellular response characterized by recovery 
of plasma membrane potential which is maintained when the cells are then incubated with low 
levels of L-AMB (at or below MICs).  In contrast, yeast cells exposed to 3 mg/L L-AMB exhibited 
a marked time-dependent impairment in membrane potential (Figure 2B). These results suggest 
that yeast cell recovery after exposure to high levels of L-AMB is related to subsequent exposure 
to nonfungicidal concentrations of L-AMB. 
Cell metabolic activity was significantly reduced by L-AMB plasma concentrations at 3 
and 6 h of incubation, remaining constant up to 24 h. In contrast, yeast cells continuously exposed 
to L-AMB at constant concentration (3 mg/L) initially displayed a high metabolic activity after 1 h 
of incubation, suggesting a different metabolic stress response. This fact is in accordance with 
the hypothesis that yeast cells exposed to antifungal pressure reprogram their metabolism in 
response to an environmental stress (Belenky et al., 2013). A previous study involving yeast 
genome-scale microarrays demonstrated that amino acid metabolism, phosphate metabolism, 
and carbohydrate metabolism genes are upregulated after treatment with 2.5 mg/L of 
Chapter III 
 
42 
 
amphotericin B (Zhang et al., 2002). After 3, 6 and 24 h of incubation with 3 mg/L L-AMB, the 
fluorescence resulting from CFDA cleavage decreased (Figure 2C); this finding can be explained 
by membrane pore formation, which may lead to the loss of fluorescence, or by an extremely 
reduced metabolic activity (Breeuwer et al., 1995). 
 Previous studies have shown that amphotericin B induces C. albicans apoptosis (Phillips 
et al., 2003; Al-Dhaheri and Douglas, 2010). According to our results, endogenous ROS 
production was induced following 6 h of L-AMB exposure (Figure 2D); this finding also was 
corroborated by results for DNA damage (Figures 3A and 3B). Notably, apoptosis was more 
evident when S. cerevisiae was exposed to 3 mg/L L-AMB than when exposed to L-AMB plasma 
concentrations, as documented by both type of assays. Interestingly, L-AMB at plasma 
concentrations did not kill S. cerevisiae cells by necrosis; in fact, cells exposed to such 
concentrations displayed no evidence of plasma membrane damage, as shown by PI staining. 
In conclusion, our results using S. cerevisiae as a model organism clearly demonstrate 
that yeast cells can respond in two ways to L-AMB: (i) expression of compensatory responses 
and survival when, in the plasma, the yeast are initially exposed to high concentrations of L-AMB 
and then much lower concentrations of the drug for extended periods of time; and (ii) induction of 
programmed cell death and/or necrosis, occurring at constant high concentrations. These findings 
provide important insights regarding L-AMB antifungal activity and may ultimately lead to the need 
to review therapeutic regimens. 
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ABSTRACT 
 
Combination of antifungal drugs with distinct targets has been used as salvage therapy, 
although without sound scientific support. In vitro studies validating such combinations are still 
scarce and the methodologies are very laborious and time-consuming. This study proposes a 
flow cytometric (FC) protocol to evaluate the effect of the combination of anidulafungin (AND) with 
amphotericin B (AMB) or azoles (fluconazole and voriconazole), tested upon 39 and 36 Candida 
strains, respectively. The concentration assayed in the combination was 0.5×MIC of each 
antifungal drug. The membrane potential marker DiBAC4(3) was used for AND-AMB association, 
and the metabolic marker FUN-1 was used for AND-azoles association. Drug interaction effect 
was determined by calculating a staining index (SI) using the sum of the percentage of 
depolarized cells (DC) after treatment with drugs combination divided by the DC of the single 
antifungal drug in the case of DiBAC4(3); the sum of the mean intensity of fluorescence (MIF) 
displayed by cells treated with the combination of drugs divided by the MIF of the single antifungal 
drug in case of FUN-1. A SI value <1 corresponds to antagonism; between 1-4 no interaction, 
and >4 synergism. The combination of AND and AMB by FC and checkerboard was synergistic 
for 46 and 43% of isolates, and antagonistic for 5 and 8%, respectively. For the combination of 
AND and azoles, it was synergistic for 36% and antagonistic for 3% by FC, and synergistic for 
44% and antagonistic for 3% by checkerboard.  When the FC method was compared to the gold 
standard checkerboard method, the agreement was 0.91 (95% confidence interval [95% CI] of 
0.88 to 0.94), sensitivity was 0.88 (CI 95% of 0.73 to 0.95), and specificity was 0.95 (CI 95% of 
0.84 to 1).  Thus, FC is a rapid and reliable method (<2 hours) to assess the effect of antifungal 
drug combinations.  
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BACKGROUND 
 
Candida species represent an important cause of invasive fungal infections with high 
morbidity and mortality rates (Richardson, 2005; Shao et al., 2007). Over the past few years, 
some epidemiological changes have been registered: the incidence of C. albicans has been 
reduced followed by a growing incidence of non-albicans species (Erjavec et al., 2009; Pfaller 
and Diekema, 2007; Tortorano et al., 2006). Late diagnosis and high mortality rates frequently 
promote the use of empiric antifungal combinations as salvage therapy without a sound scientific 
basis (Baddley and Pappas, 2005). The availability of new antifungal drugs with novel targets of 
action has enlivened the interest in combination therapy. Likewise, it is not possible to assume 
that the simultaneous administration of two or more drugs with distinct mechanisms of action 
would improve the clinical outcome compared to monotherapy (Chamilos and Kontoyiannis, 
2006). It is unknown whether a combination might reduce the effectiveness of each drug or 
increase the potential for drug interactions or even toxicity, keeping in mind that this carries a 
significantly increased cost to the health care system without previously proven clinical benefits 
(Cuenca-Estrella, 2004). Thus, it is important and timely to critically evaluate the role of 
combination therapy.  
The methods available for studying drug combinations are few and cumbersome and 
often provide contradictory results. The most commonly utilized are the checkerboard method 
(based on a mathematical model) and the time-kill assay, both impossible to implement in the 
routine of clinical laboratories because they are very laborious (Lewis et al., 2002; White et al., 
1996). Therefore, the Etest was proposed as an alternative; however, it also has serious 
limitations, including cost, despite its good correlation with the classical method. The Etest is 
difficult to interpret when dealing with the azoles, due to the inconsistent growth patterns, and at 
least 24 hours are needed to provide results, since it is based on microbial growth (Lewis et al., 
2002). Critical patients need a rapid response. 
Flow cytometry (FC) is a valuable tool for studying antifungal susceptibility, since it can 
be used to detect different physiological cell stages by using the appropriate fluorescent markers 
(Chaturvedi et al., 2004; Czechowska et al., 2008). FC susceptibility testing to azoles, 
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amphotericin B (AMB), and echinocandins has already been described (Pina-Vaz et al., 2001a; 
Pina-Vaz et al., 2001b; Pina-Vaz C, 2010; Ramani et al., 1997; Rudensky et al., 2005).  
The goal of this study was to develop an FC protocol to characterize the effects of the 
combinations of AMB or azoles with the echinocandin anidulafungin (AND) upon Candida spp. 
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MATERIAL AND METHODS 
 
Fungal strains 
 
Thirty-nine Candida strains were tested regarding the association between AND and 
AMB: 14 Candida albicans, 8 C. glabrata, 9 C. parapsilosis, 4 C. tropicalis, 1 C. guilliermondii, 2 
C. krusei and 1 C. lusitaniae. For the association between AND and azoles (fluconazole [FLU] or 
voriconazole [VOR]), 36 strains were tested: 16 C. albicans, 9 C. glabrata, 7 C. parapsilosis, 7 C. 
tropicalis, and 1 C. krusei. Clinical isolates of Candida spp. with a previously characterized 
antifungal susceptibility phenotype were selected from the collection of the Department of 
Microbiology, Faculty of Medicine of Porto, Portugal, in order to study all possibilities: susceptible 
or nonsusceptible to both drugs or susceptible to one and nonsusceptible to the other. C. albicans 
ATCC 90028 was used as the reference strain. Before the initiation of each experiment, the yeasts 
were subcultured twice on Sabouraud agar (Liofilchem, Teramo, Italy) to ensure both the viability 
and that the culture was pure. 
 
Drugs and chemicals 
Stock solutions of AMB (Sigma-Aldrich, Taufkirchen, Germany), FLU (Sigma) VOR, and 
AND (Pfizer, New York, USA) were prepared as recommended by the CLSI protocol M27-A3 
(CLSI, 2008) and stored at – 80°C. Fluorescent dyes 2-chloro-4-(2,3-dihydro-3-methyl-[benzo-
1,3-thiazol-2-yl]-methylidene)-1 (FUN-1), and Bis-(1,3-dibutylbarbituric acid) trimethine oxonol) 
[DiBAC4(3)] (both acquired from Molecular Probes, Leiden, Netherlands) were prepared in 
phosphate-buffered saline (PBS) (Sigma) and kept at – 20°C. 
 
Checkerboard microdilution studies 
Checkerboard assays were performed for AND plus AMB, and for AND plus azoles (FLU 
or VOR). MIC values of each antifungal and for the associations were determined after 24 hours 
of incubation. The concentrations tested for each antifungal ranged between 0.06 to 32 mg/L for 
FLU, 0.015 to 8 mg/L for VOR and AMB, and 0.06 to 2 mg/L for AND. Endpoints were determined 
according to values defined by the M27-A3 protocol (CLSI, 2008). The fractional inhibitory 
concentration index (FICI), which is defined as the sum of the MIC of each drug when used in 
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combination divided by the MIC of the drug when used alone, was calculated to determine the 
interaction effect; a FICI ≤ 0.5 represents synergism, >0.5 to 4 represents no interaction, and  > 
4 represents antagonism  (Johnson et al., 2004; Odds, 2003). 
 
Flow cytometry studies 
For FC assays, the strains were subcultured in Sabouraud broth and incubated with 
agitation at 35°C until the exponential growth phase in order to obtain a homogenous population 
and thus, to correlate the perturbations in cellular parameters observed by FC with the drug 
action, independently of the growth phase. Then, 0.5 MacFarland density yeast suspensions were 
prepared in PBS, corresponding to 106 yeast cells/mL. The cell suspensions were incubated at 
35ºC with subinhibitory concentrations (0.5 x MIC value) of each antifungal alone and in 
combination as described above. In order to standardize the FC protocol for all strains, the 0.5 x 
MIC of each drug was chosen since the breakpoints to AND and FLU are being reviewed, and 
their values are species dependent, and because antagonistic and synergistic classifications 
usually rely on deviations from additivity (Yeh et al., 2009; Pfaller et al., 2011a, b). According to 
the Loewe additivity definition, 0.5× MIC of drug A combined with 0.5× MIC of drug B is equivalent 
to 1 MIC of drug A or 1 MIC of drug B in an additive drug pair (Yeh et al., 2009). Even so, for 
strains inhibited at high MIC values and that do not present antagonism with the combination of 
0.5× MIC, a new test was carried out using the breakpoint of the drug (e.g., 8 mg/L for FLU and 
4 mg/L for AND) in order to evaluate its clinical significance. 
Following 1 h of incubation, the cells were washed and incubated for 15 min in the dark 
at room temperature with 0.5 mg/L of DiBAC4(3), a lipophilic anion able to diffuse across 
depolarized membranes, in the case of the association of ANB plus AMB, and with 0.5 mg/L of 
FUN-1, a metabolic marker, in the case of association of AND plus azoles. The intensity of 
fluorescence of 30,000 cells was registered at FL1 (530 nm) for DiBAC4(3), and FL2 (575 nm) for 
FUN-1. The samples were analyzed in a FACSCalibur Cytometer (BD Biosciences, Sydney, 
Australia) standard model equipped with 3 photomultipliers (PMTs), standard filters, and a 15 mW 
488 nm Argon Laser and using cell Quest Pro software (version 4.0.2). Instrument controls 
followed the standard procedures described by the manufacturer. All trials were performed in 
triplicate. The evaluation of in vitro drug interactions by FC was determined according to the 
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staining index (SI), which is similar to FICI described above. The SI was calculated as the sum of 
the percentage of depolarized cells (DC) after treatment with drugs combination divided by the 
DC of the drug alone for DiBAC4(3), and the sum of mean intensity of fluorescence displayed by 
cells treated with drugs combination divided by the fluorescence of the drug alone for FUN-1. 
Hence, SI = (DC AND+AMB/DC AND) + (DC AND+AMB/DC AMB) for AND-AMB association, 
and SI = (MIF AND+azole/MIF AND) + (MIF AND+azole/MIF azole) (MIF, ratio between mean 
fluorescence intensity of fluorescence of treated cells and viable cells) for AND-azoles 
association. Taking into account the standard classification of the checkerboard results, an 
association provided by FC was defined as antagonistic (A) for SI < 1, no interaction (NI) for SI 
between 1 and 4, and synergistic (S) for SI > 4. 
 
Determination of viable cells 
The number of viable cells in each FC assay was determined by plating 100 µL of serial 
dilutions on Sabouraud agar medium and incubating at 35ºC for 24 h. Afterwards, the number of 
colony forming units (CFU) was determined. No carryover antifungal effect was detected. All 
assays were performed in triplicate.  
 
Statistical analysis 
To evaluate the agreement between the checkerboard and FC studies, the proportion of 
agreement (PA) and the value of Kappa (K) were calculated (Sabin, 2000). In order to check the 
diagnostic validity of FC to detect the effect of the AND with AMB or azoles, having the 
checkerboard method as the reference, sensitivity and specificity were calculated (with 
confidence intervals at 95%). For calculation of all measures, the SPSS program (version 19.0) 
was used. 
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RESULTS 
 
A protocol for evaluation of AND and AMB susceptibility by FC using DiBAC4(3) as a 
marker was optimized. Our method is indeed able to discriminate for both drugs the susceptible 
and nonsusceptible Candida strains. A typical example of FC analysis for antifungal susceptibility 
testing is represented in Figure 1. Accordingly, for each strain, the autofluorescence of the cell 
population in analysis is measured. This value is always represented on the first decade of the 
log scale of intensity of fluorescence, while the ethanol-treated cells (dead cells, the positive 
control) showed a high increase in the green fluorescence intensity (FL1 [530 nm]) as expected. 
The viable nontreated cells stained with DiBAC4(3) had a slight increase in the fluorescence (2-
fold) in comparison with the viable nontreated and nonstained cells (autofluorescence). Treatment 
of susceptible strains with AND produced a dose-dependent increase for the fourth decade of 
intensity of fluorescence of cells, which was not observed in the nonsusceptible strains (Figures 
1A and 1B).  
 
 
Figure 1 - In vitro antifungal activities of anidulafungin and amphotericin B. Distribution of fluorescence 
intensity of the C. albicans 0207 AND-susceptible strain (A), C. parapsilosis 0136 AND-nonsusceptible strain 
(B), C. albicans O207 AMB-susceptible strain (D), and C. lusitaniae D51 AMB-nonsusceptible strain (E). In 
each histogram, the autofluorescence is represented by line (a); line (b) represents the fluorescence of 
untreated cells stained with DiBAC4(3); line (c) is the fluorescence of cells treated with 70% ethanol and 
stained with DiBAC4(3) (positive control); line (d) is the fluorescence of cells treated with 1 mg/L of antifungal 
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drugs during 1 h and stained with DiBAC4(3). (C, F) Determination of the number of CFU (CFU/mL) of cell 
suspensions treated with different antifungal concentrations under conditions identical to those of the flow 
cytometric assay. The nonsusceptible strain is represented by the dark-gray bars and the susceptible strain 
by the light-gray bars. 
 
The results obtained after 2 h of incubation with the antifungal were similar to data after 
1h (data not shown). This increase in fluorescence intensity corresponds to a decrease in the 
number of CFU (Figures 1A to 1C). 
Likewise, treatment of susceptible strains with 1 mg/L of AMB also induced an increase 
in fluorescence intensity similar to that of the positive control after 1 h of incubation. In contrast, 
for strains having higher MIC values, only a slight increase in fluorescence intensity was observed 
after incubation with AND or AMB, highlighting the fact that plasma membrane depolarization is 
dependent on antifungal action, and thus dependent on the antifungal susceptibility profile 
(Figures 1D and 1E). The CFU values determined in similar conditions agree very well with the 
FC data (PA = 0.92) (Figures 1C and 1F).  
Since azole treatment did not result in any increase in the intensity of fluorescence after 
DiBAC4(3) staining, even after 2 h of incubation, neither in susceptible or in nonsusceptible strains 
(data not shown), a different fluorescent probe was chosen. FUN-1, a metabolic marker, has 
already been demonstrated by our group to be an excellent probe for azole susceptibility testing 
of Candida spp. (Pina-Vaz et al., 2001b). Thus, we developed an FC protocol to evaluate FLU, 
VOR, and AND susceptibility by FC using FUN-1 as a marker (Figure 2). An increase in the 
intensity of fluorescence was registered only for susceptible strains after 1 h of incubation. 
Conversely, this increase was not found for nonsusceptible strains as expected (Figures 2B and 
E). The CFU values were consistent with FC data (PA = 0.86) (Figures 2C and 2F). 
Regarding the antifungal association studies, the FC assays for antifungal associations 
were performed with subinhibitory concentrations (0.5× MIC values) of each drug either alone or 
in association using the previous optimized conditions (Figures 1 and 2). These values were used 
to be able to standardize since the MIC varies for each strain. DiBAC4(3) was used for staining 
cells treated with AND-AMB and FUN-1 for staining cells treated with AND-FLU or AND-VOR. A 
typical synergistic interaction of AND-AMB evaluated by FC is represented in Figure 3A. The lack 
of interaction between AND and FLU association is represented in Figure 3B.  
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Figure 2 - In vitro antifungal activities of anidulafungin and fluconazole. Distribution of fluorescence 
intensity of C. albicans 0207 AND-susceptible strain (A), C. parapsilosis 0136 AND-nonsusceptible strain 
(B), C. albicans O223 FLU-susceptible strain (D), and C. albicans O216 FLU-nonsusceptible strain (E). In 
each histogram, the autofluorescence is represented by line (a); line (b) represents the fluorescence of 
untreated cells stained with FUN-1; line (c) is the fluorescence of cells treated with 70% ethanol and stained 
with FUN-1 (positive control); line (d) is the fluorescence of cells treated with antifungal drugs (1 mg/L of 
AND and 16 mg/L of FLU) during 1 h and stained with FUN-1. (C, F) Determination of the number of CFU 
(CFU/mL) of cell suspensions treated with different antifungal concentrations under conditions identical to 
those of the flow cytometric assay. The nonsusceptible strain is represented by the dark-gray bars and the 
susceptible strain by the light-gray bars. 
 
Taking into account the FC data, the association between AND and AMB was synergistic 
in 46% of cases (18 of 39); there was no interaction in 49% of isolates (19 of 39), and the 
association was antagonistic in 5% (2 of 39) (Table 1). The association between AND and FLU 
was synergistic in 36% of cases (13 of 36), there was no interaction in 61% (22 of 36), and the 
association was antagonistic in 3% (1 of 36) (Table 2). The association between AND and AMB 
evaluated by the checkerboard microdilution method was synergistic in 43% of strains tested (17 
of 39), there was no interaction in 49% (19 of 39), and the association was antagonistic in 8% (3 
of 39). Antagonistic interaction was detected only for C. albicans. For C. glabrata isolates, this 
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association was quite promising since there was no evidence of an antagonistic effect and “no 
interaction” was not a frequent event (Table 1). 
 
 
 
Figure 3 - Evaluation of antifungal combination effect using flow cytometry. (A) Flow cytometric 
analysis of the combination effect between anidulafungin and amphotericin B on the C. albicans O215 strain, 
an example of synergistic association. Line (a), fluorescence of untreated cells stained with DiBAC4(3); line 
(b), fluorescence of cells treated with 70% ethanol and stained with DiBAC4(3); line (c), fluorescence of cells 
treated with antifungal drugs and stained with DiBAC4(3); C1, cells treated with a subinhibitory concentration 
of AND (0.5× MIC); C2, cells treated with a subinhibitory concentration of AMB (0.5× MIC); and C3, cells 
treated with a subinhibitory concentrations of both antifungal drugs in association (AND 0.5× MIC + AMB 
0.5× MIC). (B) Flow cytometric analysis of the combination effect between anidulafungin and fluconazole on 
the C. albicans OL196 strain, an example of indifferent association. Line (a), fluorescence of untreated cells 
stained with FUN-1; line (b), fluorescence of cells treated with 70% ethanol and stained with FUN-1; line (c), 
fluorescence of cells treated with antifungal drugs and stained with FUN-1; C1, cells treated with a 
subinhibitory concentration of AND (0.5× MIC); C2, cells treated with a subinhibitory concentration of FLU 
(0.5× MIC); and C3, cells treated with subinhibitory concentrations of both antifungal drugs in association 
(AND 0.5× MIC + FLU 0.5× MIC). 
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Table 1 - In vitro interaction of anidulafungin and amphotericin B by the checkerboard and flow 
cytometry methods against 39 Candida species. 
Fungal strains 
Checkerboard MIC (mg/L)   Flow cytometry DC (%) 
AND AMB AND/AMB 
FICI 
(Interpretation)   AND AMB AND/AMB 
SI 
(Interpretation) 
C. albicans O236 0.25 0.25 0.125/0.03 0.62 (NI)   45.04 13.53 22.42 2.15 (NI) 
C. albicans O223 0.25 0.125 0.06/0.015 0.36 (S)   71.23 14.58 69.08 5.71 (S) 
C. albicans O216 0.125 0.25 0.06/0.015 0.54 (NI)   49.68 8.24 25.17 3.56 (NI) 
C. albicans O189 0.25 0.125 0.06/0.015 0.36 (S)   26.33 1.78 24.77 14.86 (S) 
C. albicans OL196 0.03 0.25 0.06/0.015 2.06 (NI)   83.45 27.89 33.56 1.61 (NI) 
C. albicans O207 0.015 0.125 0.06/0.015 4.12 (A)   48.96 10.45 8.53 0.99 (A) 
C. albicans O245 0.015 0.25 0.06/0.015 4.06 (A)   48.13 37.23 20.21 0.99 (A) 
C. albicans O237 0.25 0.25 0.06/0.015 0.30 (S)   42.59 1.57 44.53 29.41 (S) 
C. albicans O183 0.015 0.06 0.015/0.015 1.25 (NI)   22.69 10.41 13.20 1.85 (NI) 
C. albicans O222 1 0.125 0.06/0.015 0.18 (S)   37.40 8.78 32.65 4.59 (S) 
C. albicans O215 0.25 0.125 0.06/0.015 0.36 (S)   68.42 13.05 65.04 5.93 (S) 
C. albicans O190 0.25 2 0.125/0.015 0.51 (NI)   19.34 11.08 17.57 2.49 (NI) 
C. albicans O195 0.015 0.125 0.06/0.015 4.12 (A)   53.12 12.98 17.89 1.72 (NI) 
C. albicans ATCC 0.03 0.06 0.015/0.015 0.75 (NI)   61.34 37.12 53.11 2.30 (NI) 
C. glabrata OL158 4 0.25 1/0.03 0.37 (S)   79.44 19.36 75.85 4.87 (S) 
C. glabrata O206 0.03 0.25 0.06/0.015 2.06 (NI)   35.48 70.21 50.81 2.16 (NI) 
C. glabrata O188 0.50 0.125 0.06/0.015 0.24 (S)   82.83 3.95 58.39 15.49 (S) 
C. glabrata OL163 0.25 0.25 0.06/0.015 0.30 (S)   73.94 15.09 57.93 4.62 (S) 
C. glabrata OL149 0.25 0.25 0.125/0.03 0.62 (NI)   75.39 36.95 58.23 2.35 (NI) 
C. glabrata O175 0.06 0.125 0.015/0.015 0.37 (S)   66.85 10.44 63.11 6.99 (S) 
C. glabrata O180 0.03 0.25 0.015/0.015 0.56 (NI)   78.27 3.01 73.13 25.23 (S) 
C. glabrata O181 4 0.06 0.015/0.03 0.50 (S)   59.89 5.66 37.48 7.25 (S) 
C. guilliermondii 33 1 0.125 0.25/0.03 0.49 (S)   23.28 2.46 21.11 9.49 (S) 
C. krusei OL16 0.25 0.25 0.06/0.015 0.30 (S)   29.72 4.81 27.58 6.66 (S) 
C. krusei O234 0.125 0.125 0.06/0.015 0.60 (NI)   14.92 2.11 10.53 5.70 (S) 
C. lusitaniae D51 0.5 2 0.25/0.25 0.63 (NI)   79.93 49.79 69.93 2.28 (NI) 
C. parapsilosis OL143 2 0.25 1/0.03 0.62 (NI)   72.14 23.71 55.46 3.11 (NI) 
C. parapsilosis O246 1 0.25 0.5/0.06 0.74 (NI)   67.93 48.06 58.03 2.06 (NI) 
C. parapsilosis ATO17 4 0.125 1/0.06 0.73 (NI)   2.94 0.34 0.78 2.56 (NI) 
C. parapsilosis OL144 2 0.25 0.06/0.03 0.15 (S)   21.15 0.63 16.10 26.32 (S) 
C. parapsilosis O204 4 0.125 2/0.06 0.98 (NI)   82.33 31.18 80.53 3.56 (NI) 
C. parapsilosis O136 2 0.125 1/0.03 0.74 (NI)   15.58 14.50 16.98 2.26 (NI) 
C. parapsilosis Cpo41 8 0.125 0.06/0.06 0.49 (S)   8.87 5.98 15.06 4.22 (S) 
C. parapsilosis O158 2 0.125 0.5/0.03 0.49 (S)   45.08 4.92 21.61 4.87 (S) 
C. parapsilosis O56 4 0.125 2/0.03 0.74 (NI)   21.72 11.53 18.67 2.48 (NI) 
C. tropicalis OL202 0.06 0.25 0.015/0.015 0.31 (S)   90.22 3.45 89.79 27.02 (S) 
C. tropicalis OL205 0.25 0.25 0.06/0.015 0.30 (S)   70.98 23.04 53.85 3.10 (NI) 
C. tropicalis OL193 0.03 0.5 0.06/0.015 2.03 (NI)   42.01 11.21 11.01 1.24 (NI) 
C. tropicalis 1304 1 0.06 0.5/0.03 1 (NI)   11.54 1.98 3.96 2.34 (NI) 
aS, synergism; A, antagonism; NI, no interaction; FICI, fractional inhibitory concentration index; DC, percentage of 
depolarized cells; SI, staining index. DC percentage is based on the use of 0.5× MIC of each drug. FICI = (MIC 
AND/AMB)/MIC AND + (MIC AMB/AND)/MIC AMB. SI = (DC AND + AMB)/DC AND + (DC AND + AMB)/DC AMB. 
 
The results of AND and FLU association were similar to that for AND and VOR. Synergism 
was observed in 44% of strains (16 of 36), no interaction in 53% (19 of 36), and an antagonistic 
effect in 3% (1 of 36). These antagonistic events were detected for only one isolate of C. 
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parapsilosis. Concerning C. glabrata, once again no antagonism was observed between AND 
and the azoles, and no interaction was also a rare event, it being detected only in two strains. For 
strains that are susceptible-dose dependent or resistant to FLU and those which are 
nonsusceptible to AND, not showing antagonism with the combination of 0.5× MIC, the results of 
the assays performed using the breakpoint concentration were similar to those obtained with 0.5× 
MIC (data not shown). 
 
Table 2 - In vitro interaction of anidulafungin and fluconazole by the checkerboard and flow 
cytometry methods against 36 Candida species. 
Fungal strains 
Checkerboard MIC (mg/L)    Flow cytometry DC (%) 
AND FLU AND/FLU 
FICI 
(Interpretation) 
 
  AND AMB AND/AMB 
SI 
(Interpretation) 
C. albicans O189 0.25 32 0.06/0.06 0.24 (S)    1.10 1.26 2.60 4.44 (S) 
C. albicans O190 0.25 64 0.06/0.015 0.24 (S)    0.48 0.48 1.24 5.13 (S) 
C. albicans O195 0.015 4 0.015/0.06 1.02 (NI)    2.70 1.62 2.34 2.31 (NI) 
C. albicans O205 0.06 2 0.06/0.015 1.01 (NI)    1.68 0.93 0.82 1.36 (NI) 
C. albicans O207 0.015 4 0.015/0.06 1.02 (NI)    2.30 1.74 1.55 1.57 (NI) 
C. albicans O216 0.25 64 0.06/0.06 0.24 (S)    4.77 3.16 7.72 4.06 (S) 
C. albicans O223 0.25 1 0.06/0.06 0.30 (S)    1.75 1.39 4.37 5.65 (S) 
C. albicans O236 0.25 16 0.06/0.06 0.24 (S)    1.10 1.03 2.17 4.08 (S) 
C. albicans O237 0.25 64 0.06/0.06 0.24 (S)    2.67 1.29 3.50 4.03 (S) 
C. albicans O245 0.015 64 0.015/0.06 1 (NI)    1.41 1.27 1.34 2.00 (NI) 
C. albicans OL122 0.125 0.5 0.125/0.015 1.03 (NI)    8.00 4.79 5.69 1.90 (NI) 
C. albicans OL160 0.03 16 0.015/0.125 0.51 (NI)    0.38 0.38 0.59 3.09 (NI) 
C. albicans OL171 0.015 0.5 0.015/0.015 1.03 (NI)    0.48 0.49 0.48 2.00 (NI) 
C. albicans OL172 0.03 16 0.015/0.125 0.51 (NI)    1.26 0.91 1.68 3.19 (NI) 
C. albicans OL196 0.015 64 0.015/0.06 1 (NI)    1.28 1.41 1.28 1.91 (NI) 
C. albicans ATCC 0.03 0.125 0.015/0.015 0.62 (NI)    1.69 1.40 1.79 2.33 (NI) 
C. glabrata O158 4 4 0.5/1 0.38 (S)    7.93 1.01 8.90 9.93 (S) 
C. glabrata O181 4 4 0.25/1 0.31 (S)    2.48 0.51 2.83 6.72 (S) 
C. glabrata O188 0.5 8 0.06/0.06 0.13 (S)    3.77 2.81 7.15 4.44 (S) 
C. glabrata O180 0.5 16 0.125/0.06 0.25 (S)    0.46 1.02 1.30 4.09 (S) 
C. glabrata O206 0.03 16 0.015/0.06 0.51 (NI)    1.88 1.80 2.04 2.22 (NI) 
C. glabrata OL149 0.25 16 0.06/0.06 0.24 (S)    2.08 1.22 3.24 4.20 (S) 
C. glabrata OL158 4 8 0.06/4 0.52 (NI)    1.27 1.01 1.14 2.03 (NI) 
C. glabrata OL163 0.25 16 0.06/0.06 0.24 (S)    1.78 1.57 1.96 2.35 (NI) 
C. glabrata OL164 0.25 8 0.06/0.015 0.24 (S)    0.96 0.62 1.61 4.29 (S) 
C. krusei OL16 0.25 64 0.125/0.06 0.51(NI)    1.10 1.06 1.15 2.13 (NI) 
C. parapsilosis Cpo41 8 0.125 0.06/0.5 4.01 (A)    1.34 1.11 0.59 0.97 (A) 
C. parapsilosis O136 4 2 0.25/2 1.06 (NI)    1.64 0.91 0.92 1.57 (NI) 
C. parapsilosis O246 2 0.5 0.25/0.25 0.625 (NI)    1.53 1.72 1.66 2.05 (NI) 
C. parapsilosis O56 4 0.5 0.5/0.25 0.625 (NI)    2.33 4.06 3.07 2.07 (NI) 
C. parapsilosis OL143 2 2 0.25/0.5 0.38 (S)    3.37 4.37 4.96 2.61 (NI) 
C. parapsilosis ATO16 4 0.25 0.5/0.06 0.37 (S)    3.10 3.53 4.31 2.61 (NI) 
C. parapsilosis OL144 2 2 0.5/1 0.75 (NI)    1.95 1.18 1.94 2.65 (NI) 
C. tropicalis OL193 0.015 2 0.015/0.06 1.03 (NI)    1.12 1.68 1.53 2.27 (NI) 
C. tropicalis OL202 0.015 2 0.015/0.06 1.03 (NI)    0.47 0.75 0.46 1.60 (NI) 
C. tropicalis OL295 0.25 2 0.06/0.06 0.27 (S)    1.43 0.98 2.57 4.42 (S) 
aS, synergism; A, antagonism; NI, no interaction; FICI, fractional inhibitory concentration index; MIF, mean intensity of 
fluorescence; SI, staining index. MIF was determined using 0.5× MIC of each drug. FICI = (MIC AND/FLU)/MIC AND + 
(MIC FLU/AND)/MIC FLU. SI = (MIF AND + FLU)/MIF AND + (MIF AND + FLU)/MIF FLU. 
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Our FC assay showed three more cases of “no interaction” than the checkerboard 
method, and there was one more case of antagonism in the checkerboard method related to one 
C. albicans strain (O195) in comparison with the FC method. The Kappa value obtained between 
both methods was 0.83 (95% CI of 0.79 to 0.87), it being 0.82 (95% CI of 0.76 to 0.88) for AND-
AMB association and 0.84 (95% CI of 0.78 to 0.90) for the AND-azoles association. The 
proportion of agreement calculated was 0.91 (95% CI of 0.88 to 0.94), namely 0.90 (95% CI of 
0.85 to 0.95) for the AND-AMB association and 0.92 (95% CI of 0.87 to 0.97) for the AND-azoles 
association. Regarding sensitivity and specificity of the FC method, considering the checkerboard 
assay as the reference methodology, sensitivity was 0.88 (95% CI of 0.73 to 0.95) for detection 
of synergistic effects, and specificity was 0.95 (95% CI of 0.84 to 1). In order to detect an 
antagonistic interaction, FC sensitivity was 0.75 (95% CI of 0.3 to 0.95), and its specificity was 1. 
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DISCUSSION 
 
The use of drugs with different mechanisms of action in association may play a key role 
in treatment of invasive fungal infections (Cuenca-Estrella, 2004; Chamilos and Kontoyiannis, 
2006). In the past few years, this combined antifungal therapy has received increased attention. 
Antifungal interaction involving Cryptococcus has been studied; however, reports on the effect of 
antifungal combinations involving the most frequent Candida spp. are less common. Most of 
these studies have demonstrated synergism, whereas others have reported no interaction and 
occasionally antagonism (Chamilos and Kontoyiannis, 2006; Rodríguez et al., 2007; Serena et 
al., 2008; Kiraz et al., 2009; Jones et al., 2010). 
Echinocandins are a novel class of antifungals that have the cell wall as their target. The 
literature addressing the relationship between such drugs and membrane-active drugs such as 
polyenes or azoles against Candida is still somewhat limited (Lewis et al., 2002; Karlowsky et al., 
2006; Kiraz et al., 2009). Importantly, drugs with different targets of action could reinforce each 
other, allowing a decrease in doses and thus reducing side effects for patients (Mukherjee et al., 
2005; Karlowsky et al., 2006). AND acts by inhibiting the 1,3-β-D-glucan synthesis, the major 
component of the fungal cell wall (Pound et al., 2010). AMB and azoles are membrane-active 
drugs; the former acts by making holes in the membrane and the latter by inhibiting ergosterol 
synthesis. Echinocandins probably enhance the effect of membrane-active drugs by increasing 
their access to the target (Baddley and Pappas, 2005; Karlowsky et al., 2006). Nevertheless, it 
cannot be assumed that the use of two or more effective drugs with distinct mechanisms of action 
would produce an improved outcome compared to the results seen with a single compound 
(Cuenca-Estrella, 2004; Chamilos and Kontoyiannis, 2006). 
Like in most previously published studies, the association between azoles or AMB with 
AND resulted, for the majority of the strains, in a synergy or no interaction (Pancham et al., 2005; 
Kiraz et al., 2009; Nishi et al., 2009). In fact, in our study, antagonism for AND-AMB association 
was observed only for three strains of C. albicans (O207, O245, O195) and one for the AND-FLU 
association in a strain of C. parapsilosis (Cpo41). Each drug alone had very low MIC values for 
these strains, but they increased following the association, although still remaining low. With 
regard to echinocandins, most authors found no antagonism between micafungin and azoles or 
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AMB (Serena et al., 2008; Nishi et al., 2009; Chaturvedi et al., 2011). Barchiesi et al. did not find 
advantages in associating caspofungin and the polyene, with the exception of C. parapsilosis, but 
the study included a much more limited number of strains (Barchiesi et al., 2007). In 
some Candida strains, echinocandins are highly active, and so the fungicidal activity may be 
difficult to improve after combination treatment (Nishi et al., 2009). Moreover, we have shown that 
the drug interaction potential is species- and strain-dependent, which enhances the importance 
of the novel protocol described here for the first time. 
The mathematic model used for the checkerboard method, which allows a quantification 
analysis after calculating the FICI, has been the most commonly used procedure to characterize 
the activity of antimicrobial combinations in clinical laboratories. Other methods, such as time-kill 
assays and Etest, have been used (Kiraz et al., 2009); however, despite their good correlation 
with the checkerboard assay, all of them take at least 24h to provide results. The terminology 
used to assign the results into interpretative categories is often a subject of debate and confusion, 
with difficult resolution (Johnson et al., 2004). Synergism and antagonism have clear and intuitive 
meanings, although “no interaction” is a somewhat subjective category without a clear clinical 
relevance (Johnson et al., 2004). 
At the moment, few but relevant reports have helped to demonstrate the value of 
cytometric assays as excellent yet underexplored tools in clinical microbiology (Rudensky et al., 
2005; Czechowska et al., 2008; Pina-Vaz and Rodrigues, 2010). Flow cytometry is a powerful 
high-throughput technology that allows the characterization of several thousands of cells per 
second, distinguishing between different physiological states. Differentiations between viable, 
intermediate, and nonviable cells are possible using fluorescent dyes. Using these tools, fast, 
reliable data could be obtained with great benefit for the patient. Echinocandin antifungal activity 
was studied using DiBAC4(3) or FUN-1, although for azoles only FUN-1 could be used after a 
short incubation time. Regarding AMB, previous studies reported the impossibility of studying its 
activity with FUN-1 (Pina-Vaz et al., 2011b). Thus, the study of the AND-AMB association was 
performed using DiBAC4(3) and that of the AND-azoles association was performed using FUN-1 
(Figures 1 to 3). DiBAC4(3) is a membrane potential marker that can enter depolarized cells, 
where it binds to intracellular proteins or membranes and exhibits enhanced fluorescence; and 
FUN-1 is a metabolic activity staining that passively diffuses through yeast cell walls. In 
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metabolically inactive cells, FUN-1 remains in the cytoplasm, displaying a green fluorescence, 
while in active cells it is processed, which results in the formation of distinct vacuolar structures 
that exhibit a red fluorescence, accompanied by a reduction in the green cytoplasmic fluorescence 
(Lee and Kwak, 1999; Pina-Vaz et al., 2001a). For both markers, an increase in fluorescence 
intensity [FL1 (530 nm) for DiBAC4(3) and FL2 (575 nm) for FUN-1] agrees with the reduction of 
CFU counts, meaning a reduction of cell viability. The FC protocols described show an excellent 
agreement with the checkerboard method and high sensitivity and specificity, thus allowing the 
study of different combinations of antifungal drugs in less than 2 h. 
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ABSTRACT 
 
Patients with multiple comorbidities are often administered simultaneously or sequentially 
antifungals and antibacterial agents, without full knowledge of the consequences of drug 
interactions. Considering the clinical relevance of liposomal amphotericin B (L-AMB), the 
association between L-AMB and six antibacterial agents was evaluated against four clinical 
isolates and one type strain of Candida spp. and two clinical isolates and one type strain of 
Aspergillus fumigatus. In order to evaluate such combined effects, the minimal inhibitory 
concentration (MIC) of L-AMB was determined in the presence of 0.5-, 1-, 2- and 4-fold peak 
plasma concentrations of each of the antibacterial drugs. Since the L-AMB/colistin (CST) 
association was the most synergic, viability assays were performed and the physiological status 
induced by this association was characterized. In addition, computational molecular dynamics 
studies were also performed in order to clarify the molecular interaction.  
The maximum synergistic effect with all antibacterial agents, except CST, was reached 
at 4-fold the usual peak plasma concentrations, resulting in 2-to 8-fold L-AMB MIC reduction for 
Candida and 2-to 16-fold for Aspergillus. For CST, the greatest synergism was registered at peak 
plasma concentration (3 mg/L), with 4-to 8-fold L-AMB MIC reduction for Candida and 16-to 32-
fold for Aspergillus. L-AMB at subinhibitory concentration (0.125 mg/L) combined with CST 3 mg/L 
resulted in: a decrease of fungal cell viability; an increase of cell membrane permeability; an 
increase of cellular metabolic activity soon after 1 h of exposure, which decreased until 24 h; and 
an increase of ROS production up to 24 h. From the molecular dynamics studies, AMB and CST 
molecules shown a propensity to form a stable molecular complex in solution, conferring a 
recognition and binding added value for membrane intercalation. 
Our results demonstrate that CST interacts synergistically with L-AMB, forming a stable 
complex, which promotes the fungicidal activity of L-AMB at low concentration. 
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BACKGROUND 
 
Fungi are recognized as major pathogens in critically ill patients. Candida and Aspergillus 
species are the most common agents of invasive fungal infections (IFIs), although other yeasts 
and filamentous fungi are becoming emerging pathogens (Gullo, 2009). In the clinical practice, 
patients at risk for IFIs often receive concomitantly or sequentially antifungal therapy and 
antibacterial agents, either for prophylactic or therapeutic purposes (Stergiopoulou et al., 2009). 
However, this procedure is often adopted without full knowledge of the consequences resulting 
from pharmacological drug interactions.  
A recent literature review showed that the combination of amphotericin B (AMB) or 
fluconazole with antibacterial agents that impair RNA or protein synthesis, such as rifampicin 
(RIF), azithromycin (AZM), clarithromycin (CLR), and tetracycline (TET), enhances the in vitro 
activity of the antifungal agent against yeast and filamentous fungi (Azevedo et al., 2015). In 
addition, Zeidler et al. demonstrated that colistin (CST), an antibiotic that targets Gram-negative 
membranes, exhibits a synergistic effect with antifungal agents belonging to the echinocandin 
class against Candida spp. According to the authors, the echinocandin weakens the fungal cell 
wall facilitating the colistin action upon fungal membranes, and, consequently, this effect 
enhances the antifungal activity of the echinocandin (Zeidler et al., 2013). These results are 
particularly promising since the available antifungal panoply is narrow, encompassing only a few 
classes of agents, and the discovery of new drugs is a slow and exhaustive process (Roemer and 
Boone, 2013). Moreover, some antifungals demonstrate limited efficacy, high toxicity, and are 
prone to the development of antifungal resistance. Therefore, the association of compounds that 
enhance the efficacy of antifungal drugs may contribute to a more effective reduction of fungal 
burden and minimize the development of resistance (Zeidler et al., 2013).    
Although the association of antifungal and antibacterial agents may have beneficial 
implications in clinical terms, little is known about the pharmacological drug interactions and the 
underlying mechanisms of synergism. While there are few studies available addressing this topic, 
it is important to stress that antagonistic or indifferent effects may also be found (Petrou and 
Rogers, 1988; Stergiopoulou et al., 2009; Venturini et al., 2011). Thus, an extensive study aiming 
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to evaluate the mechanisms involved in the association between antifungal and antibacterial 
agents upon fungal growth inhibition is mandatory. 
We hereby propose to evaluate the association between liposomal amphotericin B (L-
AMB) and several antibacterial drugs against Candida spp. and Aspergillus fumigatus, as well as 
to unveil the mechanisms underlying such drug interactions. In the case of synergistic interaction, 
we have investigated using molecular dynamics (MD) simulations whether (i) the antibacterial 
agent has an intrinsic activity upon fungal cells; or (ii) the antibacterial agent acts as a facilitator 
of AMB activity. Molecular dynamics simulations have been widely applied to study the interaction 
of AMB molecules with the fungal membranes, since the mechanism of action of AMB is not well 
characterize (Baginski et al., 1997; Sternal et al., 2004; Czub and Baginski, 2006; Czub et al., 
2007; Neumann et al., 2009; Cohen, 2010; Foglia et al., 2014). Thus, this approach may be 
essential to unveil the mechanism of synergism. 
Our results demonstrate which antibacterial agents improve L-AMB efficacy and elucidate 
about the hypothetical underlying mechanism. 
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MATERIAL AND METHODS 
 
Strains and growth conditions 
 
Four Candida clinical isolates and one type strain (C. albicans 596, C. albicans 38, C. 
glabrata 590, C. krusei 120, and C. albicans ATCC 90028) and two clinical isolates and one type 
strain of Aspergillus fumigatus (A. fumigatus 76, A. fumigatus 88, and A. fumigatus ATCC MYA-
3626) were used in this study. Clinical isolates of Candida spp. and A. fumigatus were obtained 
from patients admitted at Centro Hospitalar S. João, Porto, Portugal. Isolates are included in the 
Collection of fungal clinical isolates deposited at Department of Microbiology, Faculty of Medicine 
of Porto, Portugal. Candida isolates were grown in Sabouraud dextrose agar (SDA; Formedium, 
Norfolk, United Kingdom) at 35 °C for 24 h (Teixeira-Santos et al., 2012); Aspergillus isolates 
were cultured in SDA at 35 °C for 72 h (Faria-Ramos et al., 2014). Escherichia coli ATCC 25922 
was also included in this study for control of antibacterial drugs. 
 
Antimicrobial drugs and susceptibility testing 
Liposomal amphotericin B (provided by Gilead Sciences, Inc, San Dimas, CA, USA), 
rifampicin (Sanofi Aventis, Anagni, Italy), azithromycin (Farmoz, Sintra, Portugal), clarithromycin 
(Alcala Farma, Madrid, Spain), colistin sulfate salt (C4461, Sigma-Aldrich, Munich, Germany), 
tetracycline (T3258, Sigma-Aldrich), and linezolid (LZD; Pfizer, New York, USA), were prepared 
according to the manufacturer’s guidelines, in order to obtain stock solutions of 2 mg/L. The 
minimal inhibitory concentration (MIC) of L-AMB was determined according to M27-A3 protocol 
and M27-S4 supplement for Candida sp. and M38-A2 protocol of Clinical and Laboratory 
Standards Institute for Aspergillus sp. (CLSI, 2008a,b and 2012). The MIC of each antibacterial 
drugs was also determined; the tested antibacterial concentrations ranged between 0.25-128 
mg/L. In order to evaluate the effect between L-AMB and the different antibacterial agents, the 
MIC to L-AMB was determined in the presence of 0.5-, 1-, 2- and 4-fold peak plasma 
concentrations of each antibacterial drug. Peak plasma levels described in the literature are: RIF 
12 mg/L (Van Ingen et al., 2011), AZM 4 mg/L (Sevillano et al., 2006), CLR 2 mg/L (Kees et al., 
1995), CST 3 mg/L (Michalopoulos and Falagas, 2006), TET 2 mg/L (Agwuh and MacGowan, 
2006), and LZD 12 mg/L (Dryden, 2011). Briefly, the drugs were diluted 2-fold in culture medium 
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in order to obtain a 1:4 dilution. Fifty microliters of each L-AMB concentration (ranging from 0.03 
to 16 mg/L) were combined with 50 µL of each of the concentration of the distinct antibacterial 
agents (described above). The plates were incubated at 35° C and the L-AMB MIC values 
determined after 24 and 48 h; MIC was the lowest concentration that prevented any discernible 
growth. Since clinical breakpoints were not yet established for L-AMB, the Candida isolates were 
classified in wild type (wt) whenever the MIC was ≤ 2 mg/L and non-wild type (nwt) when the MIC 
was > 2 mg/L according to the epidemiological cutoff values (ECVs) proposed by Pfaller and 
Diekema (Pfaller and Diekema, 2012). For A. fumigatus, the clinical breakpoint (CBP) for L-AMB 
is 1 mg/L (Elefanti et al., 2014). C. albicans ATCC 90028 and A. fumigatus ATCC MYA-3626 type 
strains were used as controls, as recommended by CLSI protocol (CLSI, 2008a,b and 2012). E. 
coli ATCC 25922 was used as a bacterial quality control to assure that antibacterial dilutions were 
correct. MIC determination assays were performed in triplicate. 
 
Evaluation of cell viability 
The evaluation of cell viability was performed with C. albicans 596, as a representative 
example, for the most synergic association, L-AMB/CST. The concentrations tested were 
selected according the susceptibility results. Yeast suspensions (106 yeast cells/mL) were 
exposed to L-AMB 0.125 mg/L alone and in combination with CST 3 mg/L, for 24 h at 35°C, 150 
rpm. Another suspension was prepared and treated with single CST 3 mg/L. At specific time 
points, 1, 3, 6 and 24 h, aliquots were collected and tested for viability. Cell viability was 
determined in triplicate by counting colony forming units (CFU). Briefly, the number of viable cells 
for each treatment was determined by plating 100 µL of serial dilutions on SDA agar medium and 
incubating at 35°C for 24 h; the number of CFUs was determined and compared with control 
plates (not exposed to drugs or exposed to each antimicrobial drug, L-AMB and CST); before 
being plated, cells were washed once and resuspended in fresh medium in order to prevent 
antifungal carryover.  
 
Functional characterization of drug interaction 
The distinct cellular physiological status resulting from the interaction between L-AMB 
and CST were assessed by flow cytometry in a time-course assay, using C. albicans 596 as a 
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representative example. A cell suspension (106 yeast cells/mL) was used in all assays described 
below. Yeast cells were incubated with single L-AMB 0.125 mg/L and in association with CST 3 
mg/L during 24 h. In order to evaluate whether there was a CST concentration-dependent effect, 
the following treatment conditions were also tested: L-AMB 0.125 mg/L with i) CST 1.5 mg/L and 
ii) CST 6 mg/L. The cellular status induced by single CST treatment was evaluated as control. At 
specific time points, 1, 3, 6 and 24 h, aliquots were collected and evaluated. All cytometric 
evaluations were performed in a FACSCalibur cytometer (BD Biosciences, Sydney, Australia) 
standard model, equipped with 3 photomultipliers, standard filters, a 15-mW 488-nm Argon laser, 
and using CellQuest Pro software (version 4.0.2). All the assays were performed in triplicate. 
 
The effect of L-AMB 0.125 mg/L alone and in association with CST 3 mg/L was evaluated 
regarding: i) membrane potential, ii) membrane integrity, iii) metabolic activity, and iv) 
endogenous reactive oxygen species (ROS) production.  
 
i) Evaluation of membrane potential 
The cell membrane potential was assessed by staining the cells with Bis-(1,3-
Dibutylbarbituric Acid) Trimethine Oxonol (DiBAC4(3), Sigma-Aldrich), as described by Teixeira-
Santos et al. (Teixeira-Santos et al., 2012). The fluorescence intensity (FI) at FL1 (fluorescent 
detector; 530 nm) was registered and a staining index (SI) was defined as the ratio between the 
FI of treated cells and the FI of non-treated cells.   
 
ii) Evaluation of membrane integrity   
Cell membrane integrity impairment was evaluated using propidium iodide (PI, Sigma-
Aldrich) staining. After antimicrobial treatment, yeast cells were stained with 1 mg/L of PI for 30 
min at 35°C, in the dark (Pina-Vaz et al., 2005). The FI was measured at FL3 (fluorescent detector; 
630 nm). The amount of injured cells in each sample was defined as the percentage of PI-positive 
cells. 
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iii) Evaluation of metabolic activity 
Metabolic changes were evaluated using 5-Carboxyfluorescein diacetate (5-CFDA, 
Sigma-Aldrich), at 10 µM final concentration. Antimicrobial treated cells were stained with 5-CFDA 
and incubated for 45 min, at 35 °C, at 150 rpm, in the dark (Liao et al., 2003). The mean intensity 
of fluorescence (MIF) was registered at FL1 (530 nm). 
 
iv) Evaluation of endogenous ROS production 
Reactive oxygen species production was evaluated as previously described (Yan et al., 
2009). In brief, yeast cells were incubated with 20 mg/L of 2’,7’-dichlorofluorescin diacetate 
(DCFH-DA, Sigma-Aldrich) for 30 min at 35°C, at 150 rpm. Cells were washed once (2,655 x g 
for 5 min at room temperature; 5417R, Eppendorf) and resuspended in phosphate-buffered saline 
(PBS, Sigma-Aldrich); afterwards, cells were treated with the antimicrobials as described in 
“Functional characterization of drug interactions” section. FI was determined at FL1 (530 nm). 
ROS production was calculated by subtracting the FI value displayed by cells treated with 
antimicrobials from that of cells treated with both antimicrobials and DCFH-DA.  
 
Simultaneously, 10 µL of the treated cell suspension were placed in a microscope slide 
for further analysis under fluorescence microscopy, in a Carl Zeiss Axiovert inverted microscope, 
using laser wavelength of 488 nm. 
 
Molecular dynamics studies 
The Automated Topology Builder (ATB) webserver was used for the AMB (C47H73NO17) 
and CST (C52H98N16O13) molecular dynamics (MD) topology parametrization, corresponding to 
the new residues name IDs D3JY and 09SS, respectively, as a GROMACS G54A7FF United-
Atom force field (Malde et al., 2011).  
The ATB derived force-field was tested in a series of independent MD simulations in an 
explicit water box. Then, AMB and CST molecules were placed in the same simulation box, 
together with 6230 SPCE water molecules, at more than 17 Å apart from each other, in order to 
avoid any computational bias. The entire MD protocol, including energy minimization, 
equilibration, and production steps, were performed using GROMACS 4.6.1 simulation package 
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(Hess et al., 2008). MD simulations were performed at the in-house Fermi GPU high performance 
computing workstation. The global charge of the system was zero and simulations run under 
periodic boundary conditions in an isothermal-isobaric (NPT) ensemble at 300K and 1.0 bar, 
during 20 ns, as described in previous studies (Branco et al., 2012).  
 
Statistical analysis  
Results are detailed as mean value and the respective standard deviations. Paired-
sample Student’s t test was used to compare the effect of L-AMB and CST alone and in 
association. 
All statistical analysis was performed using the SPSS software (v. 23.0). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Unveiling the synergistic interaction between L-AMB and CST 
 
71 
 
RESULTS 
 
Susceptibility to L-AMB alone and in association with antibacterial drugs  
Single RIF, AZM, CLR, CST, TET, and LZD did not inhibit the growth of all the fungal 
species studied, even at the maximum tested concentrations (4-fold peak plasma concentrations). 
The fungal strains showed variable susceptibility profiles to L-AMB, being all Candida strains wild-
type (MIC value ≤ 1 mg/L), except C. krusei with a MIC value of 8 mg/L. Regarding A. fumigatus 
MIC values of 2 and 4 mg/L were registered (Table 1).  
 
Table 1 – Minimal inhibitory concentration (MIC) of liposomal amphotericin B alone and in association with several 
antibacterial drugs at 4-fold peak plasma concentrations. 
Fungal isolates 
MIC value of L-AMB (mg/L) 
 L-AMB in association with 
L-AMB RIF AZM CLR CST TET LZD 
C. albicans ATCC 90028 1 0.25 0.25 0.25 0.125 0.25 1 
C. albicans 596 1 0.125 0.25 0.25 0.125 0.25 1 
C. albicans 38 0.5 0.06 0.25 0.25 0.06 0.25 0.5 
C. glabrata 590 0.25 0.125 0.125 0.125 0.06 0.125 0.25 
C. krusei 120 8 2 4 8 2 2 8 
A. fumigatus ATCC MYA-3626 1 0.25 0.5 0.25 0.06 0.125 1 
A. fumigatus 676 4 1 1 1 0.125 0.25 4 
A. fumigatus 88 2 0.5 1 0.5 0.125 0.125 2 
L-AMB, liposomal amphotericin B; RIF, Rifampicin; AZM, Azithromycin; CLR, Clarithromycin; CST, Colistin; TET, 
Tetracycline; LZD, Linezolid. 
 
Minimal inhibitory concentration of L-AMB was reduced 2-to 4-fold in the presence of 
peak plasma concentrations of RIF, AZM, CLR and TET. The maximum effect of these 
antibacterial agents was obtained at 4-fold plasma concentrations with a reduction of L-AMB MIC 
of 2-to 8-fold, in the case of Candida (except CLR regarding C. krusei 120) and 2-to 16-fold for A. 
fumigatus (Table 1). CST at 0.5-fold peak plasma concentration (1.5 mg/L) resulted in a reduction 
of L-AMB MIC of 2-to 4-fold for all fungal isolates tested. At the peak plasma concentration (3 
mg/L), CST reduced L-AMB MIC in 4-to 8-fold for Candida spp. and 16-to 32-fold for A. fumigatus. 
Interestingly, CST at 2- and 4-fold peak plasma concentration (6 and 12 mg/L, respectively) 
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resulted in the same effect upon L-AMB MIC as CST 3 mg/L. Linezolid, even at 4-fold peak plasma 
concentration did not associate with any L-AMB MIC reduction, regarding all tested fungal strains. 
Colistin was selected for further studies since it was the drug that exhibited the highest 
synergistic effects with L-AMB. 
 
Impact of L-AMB/CST association upon: 
i) Fungal cell viability 
Figure 1A represents C. albicans 596 viability at subinhibitory concentration of L-AMB 
(0.125 mg/L), alone and in association with CST 3 mg/L. Treatment with L-AMB 0.125 mg/L 
significantly decreased yeast cell viability up to 3 h of exposure (p = 0.039); however, after 3 h of 
treatment, cells recovered the ability to replicate and viability increased up to 24 h. At this time 
point, a significant difference was registered between cells treated with L-AMB and non-treated 
cells (p = 0.011). In the case of cells exposed to CST, significant growth reduction was only 
registered after 24 h of incubation (p = 0.009). Whenever cells were treated with L-AMB in 
association with CST there was a significant reduction of CFU counts (107 to 105 cells/mL) soon 
after 3 h of incubation (p = 0.037). This CFU reduction was consistently observed along the time 
up to 24 h (p = 0.004).  
 
ii) Cell membrane permeability 
L-AMB acts on fungal cells by binding to the sterol component of the cell membrane, first 
leading to alterations in cell permeability (Gray et al., 2012). In order to evaluate whether 
antibacterial agents improve the effect of L-AMB on cell membrane permeability, the membrane 
potential and cell membrane integrity were assessed with the fluorescent dyes DiBAC4(3) and PI, 
respectively. DiBAC4(3) enters only in depolarized cells, where it binds reversibly to intracellular 
components, resulting in an increased fluorescent signal. The results obtained regarding 
membrane depolarization of C. albicans 596 are depicted in Figure 1B; after 3 h of treatment, the 
SI of cells exposed to L-AMB 0.125 mg/L was 2.65 (p = 0.173); at 6 h, the SI increased to 3.88 (p 
= 0.043), remaining constant up to 24 h (p = 0.042). Whenever yeast cells were exposed to CST, 
the SI was about 1.00 up to 6 h of treatment (p = 0.082), increasing to 2.36 at 24 h (p = 0.052). 
Regarding the association of L-AMB 0.125 mg/L with CST 3 mg/L, soon after 1 h of treatment the 
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SI was 3.79, increasing up to 14.38 following 24 h. Significant differences were observed between 
the association L-AMB/CST and single L-AMB at 1 h (p = 0.025), 3 h (p = 0.028), 6 h (p = 0.011), 
and 24 h (p = 0.011). L-AMB 0.125 mg/L in association with CST 1.5 mg/L induced an increase 
of SI up to 24 h (SI = 6.69) (p = 0.028). This effect was more pronounced when L-AMB 0.125 
mg/L was combined with CST 3 mg/L, as previously described. However, when L-AMB 0.125 
mg/L was combined with CST 6 mg/L no significant differences were found, compared to the 
association L-AMB/CST (3 mg/L) (data not shown). Such results show the key role of L-AMB/CST 
association on the increase of cell membrane depolarization.  
Conversely, PI is a cell viability marker, which enters cells only when membrane has been 
seriously injured. The results regarding membrane lesion of C. albicans 596 are represented in 
Figure 1C. In cells treated with L-AMB 0.125 mg/L, the % of PI(+) cells after 1 h of exposure was 
about 10.00%, increasing slightly up to 24 h (% of PI(+) cells  = 14.93); significant differences 
were found at 1 h (p = 0.019), 3 h (p = 0.036), 6 h (p = 0.008), and 24 h (p = 0.036), compared to 
control (non-treated cells). Cells treated with CST 3 mg/L showed PI-uptake only after 24 h of 
incubation, with a % of PI(+) cells equal to 5.93 (p = 0.046). Concerning the L-AMB/CST 
association, soon after 1 h of exposure, PI stains 21.82% of the treated cells, and after 6 h of 
incubation, this value reaches 39.47%; at 24 h, the percentage of cells with membrane lesion was 
about 45.01%. Significant differences were observed between the L-AMB/CST association and 
L-AMB treatment at 1 h (p = 0.011), 3 h (p = 0.008) 6 h (p = 0.002), and 24 h (p = 0.040). Thus, 
data suggests that L-AMB/CST association promotes the membrane lesion effect of L-AMB, in a 
time-dependent fashion.   
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Figure 1 - Effect of liposomal amphotericin B in combination with colistin upon C. albicans (strain 
596) physiological parameters. (A) Viability assessment by colony forming units (CFU) enumeration of C. 
albicans cells exposed to (■) L-AMB, (■) CST, and (■) L-AMB in association with CST. The CFU counts of 
cells non-treated are represented as (■). (B) Cell membrane potential was evaluated using DiBAC4(3) 
staining. (C) Cell membrane integrity was evaluated using propidium iodide (PI) staining. (D) Cell metabolic 
activity was evaluated using 5-CFDA staining. Data at respective time points corresponds to mean ± 
standard deviations. *p values < 0.05, significant differences between the treatments with L-AMB alone and 
CST alone vs. the control (non-treated cells); and between the association L-AMB/CST and L-AMB alone. 
 
iii) Metabolic activity 
To assess the metabolic effects of L-AMB/CST upon C. albicans 596, the cells were 
stained with 5-CFDA; 5-CFDA is a cell-permeant esterase substrate that measures enzymatic 
activity (Breeuwer et al., 1995; Boender et al., 2011). Only the cells metabolically active will 
display a high level of fluorescence. The results obtained for MIF are detailed in Figure 1D. Mean 
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intensity of fluorescence displayed by viable cells (not exposed to the drugs) remained constant 
up to 24 h; at this time point, the MIF was 176.99. Cells treated with L-AMB did not display 
significant differences in MIF up to 3 h (p = 0.198). After 6 h, MIF decreased over time up to 75.53 
(p = 0.049) at 24 h of exposure. When yeast cells were treated only with CST 3 mg/L, the MIF 
increased after 1 h (322.59) (p = 0.029), indicating that the cells were metabolically active. 
However, after 3 h of treatment, the MIF decreased up to a value of 172.11 (p = 0.220), at 24 h, 
similar to the MIF of cells not exposed to the drugs. Cells exposed to the association L-AMB/CST 
initially displayed a very high MIF (724.30); however, it decreased until 24 h of treatment (234.91). 
Significant differences were registered between the metabolic activity of cells exposed to the drug 
association and to L-AMB alone at 1 h (p = 0.001), 3 h (p = 0.021) 6 h (p = 0.014), and 24 h (p = 
0.025).  
 
iv) Endogenous ROS production 
Reactive oxygen species production was assessed by DCFH-DA staining. DCFH-DA is 
oxidized to highly fluorescent 2’,7’-dichlorodihydrofluorescein (DCF) by ROS. ROS production by 
cells exposed to L-AMB 0.125 mg/L was constant up to 6 h of incubation (≈ 7.00%) (p = 0.005); 
at 24 h, the number of fluorescent cells increased up to 18% (p = 0.001) (Figure 2A). Exposure 
to CST 3 mg/L resulted in reduced ROS formation in C. albicans 596 cells, reaching a value of 
7.00% (p = 0.010), following a 24 h of incubation. Images obtained by fluorescence microscopy 
(Figure 2B) showed vesicle formation in the presence of CST, after 24 h of incubation. Cells 
exposed to L-AMB/CST displayed a growing ROS production pattern; 7.00% following 6 h (p = 
0.056); 25.53% following 24 h of incubation (p = 0.022) (Figure 2A). These results reveal that L-
AMB/CST leads to an increase of intracellular accumulation of ROS in relation to single L-AMB 
after 24 h. 
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Figure 2 - Effect of liposomal amphotericin B (L-AMB) in association with colistin upon endogenous 
ROS production.  (A) Endogenous reactive oxygen species (ROS) production determined by DCFH-DA 
staining, assessed by flow cytometry. (B) Fluorescence microscopy imaging showing ROS-positive cells 
after treatment with b) L-AMB and c) CST alone and d) in association after 24 h of exposure; a) control, non-
treated cells.  *p values < 0.05, significant differences between the treatments with L-AMB alone and CST 
alone vs. the control (non-treated cells); and between the association L-AMB/CST and L-AMB alone. 
 
Self-association propensity assessed by atomic molecular dynamics simulations 
It is known the propensity of AMB to form dimeric or even higher complex tetrameric structures 
once in water medium, which interfere with the electrophysiology of living cells through 
transmembrane ion channel formation (Starzyk et al., 2014). Herein, we describe the propensity 
of AMB and CST in water also to self-assembly based on molecular dynamics simulations. The 
results demonstrate that the two molecules tend spontaneously form a natural complex in 
solution, starting from a perfect unbound, solvated form, separated by more than 17 Å. Once the 
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two molecules meet each other after the first 4 ns of simulation, they are steadily attracted into a 
complex formation that stands stable for the rest of the simulation time. This complex is 
characterized by polar interactions, namely hydrogen bond interactions between the C5- and C9-
OH groups of AMB and amide groups of CST, as depicted in Figure 4A and B. These two H-bond 
pairs (AMB-O58:CST-N18 and AMB-O66:CST-O9) converged for a minimum distance of 2.7 Å and 
2.5 Å, respectively. It seems that the complex is quite stable on the simulation window, supporting 
an analogous mechanism to the one predicted and validated experimentally for the dimerization 
of AMB alone. However, the main dimer-stabilizing contacts of the AMB:CST system seems to 
be the polar interactions and not the van der Waals forces contribution, as described for the 
hydrophobic nature of dimerization process of AMB molecules, which still might be essential for 
speeding up transmembrane intercalation of the complex and consequent disruption of the cell 
membrane through pore formation, resulting into a perfect and synergetic Trojan mechanism for 
the antimicrobial internalization (Starzyk et al., 2014). 
 
Figure 3 - Self-assembly of amphotericin B (AMB) and colistin (CST) (represented in sticks) in water 
medium (represented in lines) through molecular dynamics (MD) simulation studies. (A) Complex 
conformation snapshot after 20 ns of simulation, including water molecules within 4 Å of the complex. (B) 
Time evolution of the h-bond distance between two molecules during the complex formation. 
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DISCUSSION 
 
This study demonstrates that all the tested antibacterial agents except linezolid interact 
synergistically with liposomal amphotericin B against several pathogenic fungi, namely C. 
albicans, C. glabrata, C. krusei, and A. fumigatus (Table1). These antibacterial agents alone did 
not exhibit antifungal activity, thus suggesting that such compounds do not intrinsically target the 
fungal cells. The agents tested belong to distinct antibacterial classes with different mechanisms 
of action. Rifampicin inhibits the DNA-dependent RNA polymerase (RNAP), leading to the 
suppression of RNA synthesis and cell death (Campbell et al., 2001). The basic architecture of 
bacterial RNAP and yeast RNAP presents several structural differences (Minakhin et al., 2001), 
explaining why RIF by itself does not display antifungal activity. Azithromycin and CLR are 
macrolide antibiotics that bind to 50S ribosomal subunits of bacteria, blocking the protein 
synthesis and inhibiting cell growth (Kanoh and Rubin, 2010; Parnham et al., 2014); LZD also 
binds to the 50S subunit of the prokaryotic ribosome, blocking the assembly of a functional 
initiation complex for protein synthesis (Livermore, 2003); TET inhibits protein translation in 
bacteria by binding to the 30S ribosomal subunit (Chopra and Roberts, 2001). Although the basic 
mechanism of protein synthesis in eukaryotes is similar to that in bacteria, some noteworthy 
differences were described between the structure of eukaryotic and prokaryotic ribosomes (Berg 
et al., 2002). Colistin belongs to the family of polymyxin antibiotics, which target bacterial cell 
membrane. CST displaces Mg2+ and Ca2+ ions, which stabilize the negatively charged 
lipopolysaccharide, disrupting the membrane integrity in gram-negative bacteria (Falagas and 
Kasiakou, 2005). The antifungal activity of polymyxin antibiotics against several fungal species 
has been previously reported (Schwartz et al., 1972); however, at the hereby tested 
concentrations, CST did not inhibit fungal growth. Colistin plasma concentrations usually range 
from 0 to 15 mg/L, with free CST levels ranging from 0.5 to 3 mg/L (Akers et al., 2015). It is 
important to emphasize that about 50% of CST molecules bind to plasma proteins (Falagas and 
Kasiakou, 2005). 
Considering all the antibiotic drug combinations evaluated, the one that resulted in the 
strongest synergic effect was L-AMB/CST. Additionally, the synergistic combination of CST with 
other antifungal agents, namely echinocandins class, has been previously described (Zeidler et 
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al., 2013). Therefore, we explored the underlying mechanism of synergism of L-AMB/CST 
interaction.  
Amphotericin B is a lifesaving antifungal drug used to treat deep-seated fungal infections, 
exhibiting broad-spectrum fungicidal activity. This activity is based on its interactions with fungal 
cell membranes (Starzyk et al., 2014). AMB primarily binds to ergosterol, inserts into the 
cytoplasmic membrane, and forms pore-like structures; the result is osmotic instability, loss of 
membrane integrity, metabolic disruption, and ultimately cell death (Gray et al., 2012). Our results 
showed a significant growth reduction of fungal cells treated with L-AMB/CST during 24 h of 
exposure (108 to 105 cells/mL), with a simultaneous increase of cell membrane permeability, as 
documented by DiBAC4(3) (SI was 14.38) and PI staining (% of PI(+) cells was 45.01%) (Figures 
1B and C). Altogether, these results strongly indicate that the association of CST significantly 
improves the fungicidal activity of L-AMB.  
It is known that yeast cells exposed to L-AMB pressure reprogram their metabolism in 
response to an environmental stress (Zhang et al., 2002; Belenky et al., 2013; Teixeira-Santos et 
al., 2015). The combination of L-AMB and CST triggered an increase of metabolic activity in 
treated cells, soon after 1 h of exposure (3.8 fold higher than single L-AMB treatment; Figure 1D), 
suggesting an early strong stress response induced by membrane permeabilization. Along 24 h 
of exposure, the metabolic activity decreased overtime, nevertheless, still exhibiting a MIF 3.1 
fold higher than single L-AMB treatment (Figure 1D). This decrease can be explained by 
membrane pore formation, which may cause the accelerated loss of fluorescence, or by a reduced 
metabolic activity (Breeuwer et al., 1995; Teixeira-Santos et al., 2015). Interestingly, the higher 
cell metabolic activity induced by the association of L-AMB/CST versus single L-AMB along 24 h 
period can be related with a higher endogenous ROS production in cells exposed to this 
association (Figure 2), which will result in oxidative damage and possibly is involved in induced 
programmed cell death (Phillips et al., 2003; Al-Dhaheri and Douglas, 2010). Curiously, single 
CST (3 mg/L) has a significant effect on ROS production by itself. Accordingly, cells exposed to 
CST display a different phenotype compared to cells exposed to the other treatment conditions, 
i.e. the formation of vesicles (apoptotic bodies), which is a characteristic event of apoptosis (Fink 
and Cookson, 2005). Although the functional studies that support the mechanism of action of L-
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AMB/CST association have been conducted only in C. albicans, according to the MIC 
determination assays, this mechanism seems to be transversal to the different species studied.  
All of our results point to a considerable improvement of L-AMB antifungal effect, at 
subinhibitory concentrations, whenever associated to CST 3 mg/L. However, how do AMB and 
CST molecules interact? The computational molecular dynamics results demonstrate that the two 
molecules spontaneously form a natural complex in solution, characterized by a strong bond 1:1. 
Thus, AMB and CST molecules act together on fungal cells. In support of such a finding was the 
fact that the maximum synergistic effect was detected in the presence of peak plasma 
concentration of CST (3 mg/L); its increase to 4-fold peak plasma concentration did not increase 
the synergistic effect, as documented by MIC determination and membrane potential evaluation 
assays. Moreover, a recent study described that the interactions of AMB with biomembranes are 
managed by the molecular organization of AMB (Starzyk et al., 2014). AMB self-associates to 
dimeric structures; AMB dimers can further assemble into tetramers, which induce the formation 
of transmembrane ion channels, impairing the electrophysiological homeostasis of a living cell 
(Starzyk et al., 2014; Davis et al., 2015). Considering all these findings, it is possible that CST 
binds to AMB molecules and accelerates the assembly of AMB tetramers, thus inducing pore 
formation on fungal cell membranes, also triggering a strong cell stress response, which is typical 
of AMB action.  
Our results are extremely promising since AMB is an important therapeutic alternative for 
the treatment of IFIs, particularly when infection persists, despite treatment with other drugs, and 
the clinical response to AMB is reduced in about 40% of treated patients (Mora-Duarte et al., 
2002; Ito and Hooshmand-Rad, 2005; Park et al. 2006). Simultaneously, this synergic association 
may be a clue for drug discovery. 
Studies are being conducted in order to characterize the functional groups of the 
AMB/CST complex that interact with the fungal membrane aiming to design a more active 
antifungal compound. 
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More than fifty years after its availability for clinical use, AMB remains a very important 
therapeutic option in case of deep seated mycosis, particularly when the infection persists despite 
treatment with azoles or echinocandin drugs. While the development of resistance is an extremely 
rare event, the clinical response to AMB often does not match the predicted response by the in 
vitro susceptibility profile (Ullmann et al., 2006; Moen et al., 2009). The present work provides 
data that suggests an explanation for the clinical failure of AMB treatment, and also propose some 
antimicrobial compounds as enhancers of AMB activity. Amphotericin B therapy may fails, not 
because fungi may acquire resistance as it happens with other antifungals (Shapiro et al., 2011); 
instead, treatment failure could be linked to other factors, including plasma AMB concentrations 
and the inability of the drug to penetrate certain niches of the patient’s body, allowing infection to 
persist (Paterson et al., 2003; Vincent et al., 2013). Based on this assumption, the yeast response 
to liposomal-AMB exposure at simulated plasma concentrations and a constant concentration 
was clarified in a comprehensive phenotypic and functional assay. Indeed, the results 
demonstrated that the effectiveness of AMB depends on the concentration and time of exposure. 
The yeast exposure to L-AMB plasma concentrations promotes a series of mechanisms at a 
distinct levels, like replicative ability, membrane integrity, metabolic activity, endogenous ROS 
production, and DNA damage, which allow homeostatic regulation and recovery from drug stress. 
While membrane depolarization and loss of replication competency is an early event (occurring 
within the first 6 h) in a phase of decline caused by exposure to high concentrations (5 to 20 
mg/L), recovery can occur at low drug concentrations, along the remaining 18 h. Yeast cells 
initially exposed to high L-AMB concentrations suffer membrane depolarization followed by pore 
formation. The membrane pores induced by L-AMB action promote ion exchange between the 
intracellular and extracellular environment (Baginski et al., 1997; Milhaud et al., 2002; Cohen, 
2014). Therefore, such an action triggers the activation of signaling pathways responsible for 
sensing and responding to the osmotic stress (Cohen, 2014). According to the AMB mechanism 
of action recently proposed, AMB firstly extracts ergosterol from lipid membranes (Anderson et 
al., 2014); as result, the pathways involved in the control of the lipid composition and ergosterol 
content of the cell membrane are activated, justifying the slightly high cellular metabolic activity 
in the first hour of exposure to high AMB concentrations. Amphotericin B has been found to 
downregulate genes involved in the biosynthesis of ergosterol, fatty acid elongases, and 
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synthetases as well as ceramide, which are enzymes and lipid precursors required for the 
biosynthesis of sphingolipids (Zhang et al., 2002; Cohen, 2014). Sterols and sphingolipids are 
important components of lipid rafts, the membrane microdomains that perform important roles in 
the targeting and activity of signaling proteins in eukaryote cells. Ergosterol is also an important 
element in fungal cell physiology, being associate to cell division, endocytosis, cell signaling, 
membrane compartmentalization, and functional regulation of membrane proteins (Mollinedo, 
2012; Cohen, 2014). Owing to the essential role of ergosterol in fungal membranes, its depletion 
leads to fungal cell death. This fact may explain the loss of replication competency during the 
firsts 6 h wherein the cells are exposed to high L-AMB concentrations. However, when L-AMB 
concentrations start to decay, the fungal cells can recover from AMB effect: cell membrane 
potential is restored during the remaining 18 h that the cells are exposed to levels of drug close 
to or below the MIC. The intracellular equilibrium of ion concentration as a result of environmental 
adaptation is restored. As a consequence, the fungal cells return to a functional physiological 
status, reestablishing the components and full biological activity of their membranes. The initial 
loss of replication competency is restored and the cells maintain constant their metabolic activity 
up to 24 h. Other authors have also confirmed this finding; yeast cells exposed to AMB have a 
capacity for “resuscitation”, although they are unable to replicate (Liao et al., 1999). This result 
may be explained by the increase, and then the decrease of AMB-L plasma concentrations that 
rapidly evoke compensatory responses in yeast cells. Residual reactive oxygen species (ROS) 
production also happened in yeast cells exposed to L-AMB at plasma concentrations after 6 h of 
exposure. The production of ROS is associated with oxidative damage, and possibly is involved 
in induced cell death. Indeed, the production of ROS induced by AMB has been described as a 
universal and important mechanism of action that is correlated with fungicidal effect, and might 
explain the low rate of resistance to AMB (Mesa-Arango et al., 2014). Notably, about 20-30% of 
cells treated with L-AMB plasma concentrations suffered apoptosis. This results indicate that 
yeast cells exposed to L-AMB at plasma concentrations, initially compensate by upregulating their 
physiological responses to minimize the drug-induced stress; when the L-AMB concentrations 
fall, the cells recover from L-AMB action, allowing the persistence of the fungal infection and 
possibly resulting in a poor clinical outcome. In contrast, yeast cells exposed to a constant 
concentration of L-AMB (3 mg/L) during 24 h, despite initially developing compensatory 
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mechanisms to counteract the drug-induced stress, as the drug concentration is kept constant, 
the cells will succumb to the drug effect. Cells constantly exposed to L-AMB 3 mg/L lose viability, 
with clear evidence of cell membrane depolarization and lesion. Soon after 1 h of exposure, the 
cell metabolic activity increased as a response to environmental stress (Belenky et al., 2013); 
afterwards, it dropped significantly up to 24 h. The endogenous production of ROS was also 
registered in cells exposed to L-AMB 3 mg/L; at 24 h, the amount of accumulated ROS was much 
higher than in cells exposed to plasma concentrations. These molecules are toxic to the cells and 
have been described as the mains mediators of programmed cell death (Madeo et al., 1999). As 
result, in cells exposed constantly to 3 mg/L, apoptosis was registered in about 60% of yeast 
cells, twice the proportion of cells exposed to L-AMB plasma concentrations. Our data suggested 
that constant L-AMB concentration induces programmed cell death and necrosis in exposed cells, 
being more effective.   
Another aim of our study was to determine whether yeast recovery mechanism to L-AMB 
effect was Candida species specific or was a transversal mechanism, common to other yeasts, 
with and without clinical relevance.  This study comprised a wide range of yeasts (pathogenic and 
nonpathogenic) with different phylogenetic relationships and distinct antifungal susceptibility 
profiles. We confirmed that in all species studied (Candida albicans, C. glabrata, C. parapsilosis, 
C. krusei, C. tropicalis, C. dubliniensis, C. lusitaniae, Cryptococcus neoformans, Saccharomyces 
cerevisiae, Debaromyces hansenii, Kluveromyces lactis, and Zygosaccharomyces rouxii), yeast 
cells exposed to initially high L-AMB plasma concentrations (5 to 20 mg/L) suffered membrane 
depolarization up to 6 h; however, when the L-AMB concentrations fell, along the remaining 18 h, 
the cell membrane repolarized and the yeasts recovered from L-AMB action. Interestingly, the 
mechanism of yeast recovery seems to be unrelated to the MIC values corresponding to the 
strains studied. In all clinical isolates, independently of the corresponding L-AMB MIC value, these 
findings were registered. Thus, the recovery mechanism to L-AMB, at low plasma concentrations, 
might be responsible for a reduced susceptibility to L-AMB and the poor correlation between in 
vitro results and clinical outcome. Moreover, the results obtained suggest that this mechanism 
might impair the in vivo fungicidal activity of L-AMB. Despite these findings may provide important 
insights about in vivo L-AMB antifungal activity, its hypothetical clinical implications should be 
interpreted with particular caution, since yeast infections are mainly located at tissues and not in 
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the plasma (Smith et al., 2007). Noteworthy, previous results involving organ biopsies revealed 
that in some tissues like the kidney and liver, drug levels main remain high overtime. However, 
such findings are not consistent when considering other organs such as the lung or the central 
nervous system (Vogelsinger et al., 2006; Smith et al., 2007). In addition, since the diagnosis of 
invasive fungal infections is often delayed, the fungal burden within the tissues can be 
considerable at the time of initiation of treatment, requiring a large amount of antifungal drug to 
be delivered to the tissues to effectively reduce the fungal burden (Jones et al., 2003; Smith et 
al., 2007). Moreover, patients with IFIs are often administered multiple medications concomitantly 
with L-AMB, usually repeated daily, which may interfere with L-AMB molecules. During the 
prolonged periods following L-AMB administration, when drug levels fall to much lower 
concentrations, the possibility that fungal organisms may recover from the antifungal effect is to 
be remembered. The present type of investigation may be useful in helping to develop appropriate 
clinical L-AMB therapeutic regimens. The therapeutic monitoring of AMB should be performed for 
a better understanding of AMB exposure-response relationship, since the pharmacokinetics and 
distribution of AMB are sometimes poor, allowing some fungi to hide at certain niches where drug 
exposure is limited (Ashbee et al., 2013, Vincent et al., 2013). This practice might increase the 
probability of a successful outcome.  However, in clinical routine the therapeutic drug monitoring 
is not performed (Ashbee et al., 2013).   
One possible alternative to improve the clinical response to L-AMB is to focus on 
combined antifungal therapy. Late diagnosis and poor response to antifungal therapy frequently 
encourages the use of empirical antifungal combination as salvage therapy, even without 
scientific base (Baddley and Pappas, 2005). Studies about the in vitro effect of antifungal 
combinations involving the most frequent pathogenic yeasts are scarce and some provide 
contradictory results (Cuenca-Estrella, 2004). Notably, the available methodologies for evaluation 
of in vitro antifungal associations are very cumbersome, time consuming, and difficult to interpret. 
We developed an original protocol based on flow cytometry for in vitro assessment of associations 
between amphotericin B and anidulafungin, and anidulafungin and azoles, against Candida 
species. Anidulafungin belongs to the echinocandin class, and inhibits 1,3-β-D-glucan synthase, 
an enzyme that is necessary for synthesis of an essential component of the fungal cell wall (Gil-
Alonso et al., 2015). AMB and azoles are membrane active drugs; the first extracts ergosterol 
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from the fungal membrane and produces pores, while the latter inhibits the ergosterol synthesis 
(Anderson et al., 2014; Ghannoum and Rice, 1999). Based on the literature, the echinocandin 
possibly facilitates the access of AMB and azoles to its target site, thus resulting in a synergistic 
effect (Baddley and Pappas, 2005 and Karlowsky et al., 2006; Kiraz et al., 2009). Despite the 
association of two antifungal drugs with distinct mechanisms of action might represent a promising 
therapeutic alternative for the treatment of IFIs, it cannot be assumed that it will improve the 
outcome in comparison to monotherapy. According with Kiraz et al., the association between 
caspofungin and amphotericin B against C. glabrata had an indifferent effect in 54-58% of tested 
isolates, and was antagonistic against 2% of the isolates (Kiraz et al., 2009). Another study has 
reported that the association between anidulafungin and fluconazole was indifferent in about 67% 
of Candida isolates tested (Karlowsky et al., 2006). These results highlighted the importance of 
critically evaluate the effect of combination therapy.  
Recent reports have demonstrated the advantages of flow cytometry for the evaluation of 
antimicrobial susceptibility profile in yeasts (Ramani et al., 1997; Pina-Vaz et al., 2001a, 2001b 
and 2010; Rudensky et al., 2005). Through the use of suitable fluorescent dyes, this approach 
allows to identify different physiological states, being able to discriminate viable cells from 
nonviable in a short time (less than 2 h). For assessment of antifungal drug combinations, we 
selected two fluorescent dyes, DiBAC4(3), and FUN-1. DiBAC4(3) is a membrane potential marker 
that enters depolarized cells, where it binds to intracellular proteins or membranes and exhibits 
enhanced fluorescence; a higher depolarization results in a higher influx of the dye, and 
consequently, an increase in cell fluorescence (Baxter et al., 2002). FUN-1 is a metabolic activity 
dye that passively diffuses through yeast cell membranes; in metabolically active cells, FUN-1 is 
converted into intravacuolar structures that exhibit orange/red fluorescence, while in metabolically 
inactive cells it remains intact in the cytoplasm, displaying green fluorescence (Pina-Vaz et al., 
2005). According to the data published, FUN-1 is not able to reveal the effect of AMB against 
yeast cells (Pina-Vaz et al., 2001a); in turn, the precocious effect of azoles can only be 
demonstrated using FUN-1 (Pina-Vaz et al., 2005). Regarding AND, the obtained results indicate 
that its activity may be studied using DiBAC4(3) or FUN-1. Thus, the study of AND/AMB 
association was performed using DiBAC4(3), while AND/azoles association was performed with 
FUN-1. This novel protocol revealed a high accuracy and an excellent agreement with the 
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checkerboard method, thus allowing the evaluation of different antifungal combinations in less 
than 2h. Nevertheless, it has the disadvantage that it can only be applied for yeasts, although 
Ramani et al., already had developed a protocol for antifungal susceptibility testing in Aspergillus 
fumigatus by flow cytometry (Ramani et al., 2003). 
The association between AND and AMB resulted mostly in synergism (46%) or no 
interaction (49%), as previously described (Rosato et al., 2012; Valentin et al., 2016); antagonism 
was only detected in C. albicans isolates (5%). The combination of other echinocandins, i.e. 
caspofungin or micafungin, with AMB was also described as potentially synergic against Candida 
isolates (Kiraz et al., 2009; Nishi et al., 2009). Regarding the association of AND with azoles, a 
synergistic effect was detected in 36% of isolates, while no interaction was found in 49% of 
isolates. The synergistic interaction between anidulafungin and azoles against Candida, Fusarium 
and Aspergillus species has also been described in other studies (Philip et al., 2005; Rosato et 
al., 2012; Siopi et al., 2016). The only case of antagonism was found in a C. parapsilosis strain. 
For C. glabrata isolates, both associations seem to be promising, since there were no cases of 
antagonism, and the cases of no interaction were few (29%). The results obtained suggest that 
drug interaction potentially is species and strain dependent, which reinforces the importance of 
the novel flow cytometric protocol hereby described. In addition, the synergic association of 
antifungal drugs seems to increase the action of each other, possibly allowing a decrease of 
individual dosage thus, reducing side effects for patients (Mukherjee et al., 2005; Karlowsky et 
al., 2006).  
Likewise, the literature has described the synergic interaction between amphotericin B 
and antibacterial agents, namely those that inhibit RNA or protein synthesis, such as rifampicin, 
azithromycin, clarithromycin, and tetracycline, against Candida and Aspergillus species (Azevedo 
et al., 2015). This kind of association may represent an important therapeutic alternative for the 
treatment of IFIs, overcoming the AMB limited efficacy and toxicity. However, there are few 
studies addressing this topic, and there is somewhat limited knowledge about the underlying 
mechanisms of synergism. In the present work, it was evaluated the association between L-AMB 
and several antibacterial drugs against Candida spp. and Aspergillus fumigatus. The association 
of RIF, AZM, CLR, CST, and TET with L-AMB was synergistic against several pathogenic fungi, 
encompassing C. albicans, C. glabrata, C. krusei, and A. fumigatus. Since these antibacterial 
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compounds alone were not active against the fungal isolates, apparently, they do not have an 
intrinsic target in fungal cells, and the synergism occurs by an unknown mechanism.  Most of 
these antibacterial agents, act at the level of bacterial polymerases (RNAP) or ribosome subunits 
(Campbell et al., 2001; Chopra and Roberts, 2001; Kanoh and Rubin, 2010; Parnham et al., 
2014). Indeed, the structure of the prokaryotic targets displays noteworthy differences in 
comparison with their homologs in eukaryotic organisms (Minakhin et al., 2001; Berg et al., 2002). 
Another possible explanation for the lack of activity upon fungal cells, is related with the difficulty 
that antibacterial agents might have in accessing a possible target in fungal cells. The fungal cell 
damaged due to AMB action, may allow entrance of antibacterial agents, inhibiting RNA/protein 
synthesis, and resulting in a synergistic effect (Azevedo et al., 2015).  Regarding colistin, its 
antifungal activity has been previously reported, although at the tested concentrations, CST did 
not inhibit fungal growth (Schwartz et al., 1972). According to our results, despite all antibacterial 
agents having improved the L-AMB fungicidal action at sub-inhibitory concentrations, the CST 
was the drug that exhibited the strongest synergistic effect. Thus, the association L-AMB/CST 
was scrutinized and the underlying mechanism described at a functional and molecular level. 
Colistin is a polymyxin antibiotic, which targets bacterial cell membrane (Falagas and Kasiakou, 
2005). The synergistic effect between CST and antifungal drugs, namely those belonging to 
echinocandin class, has been described (Zeidler et al., 2013). The functional studies shown that 
L-AMB in association with CST induced a significant cell growth reduction compared with single 
L-AMB treatment. At the same time, cells exposed to L-AMB/CST suffered an increase of 
membrane permeability throughout 24 h. In the first hour of treatment, cells shown a high 
metabolic activity. As previously mentioned, the drug-induced stress triggers an increase of cell 
metabolic activity in the first hours of exposure. Signaling pathways are activated in order to 
maintain cellular structure and function (Zhang et al., 2002; Cohen, 2014). Afterwards, the 
metabolic activity of cells exposed to this association decreased overtime. The initial high 
metabolic activity of cells exposed to this association can be related with an intense endogenous 
ROS production, resulting in oxidative damage for cells, which can lead to induced programmed 
cell death (Mesa-Arango et al., 2014). The cells exposed to single L-AMB treatment suffered a 
similar effect, however, less pronounced than in cells exposed to L-AMB/CST association. All 
these findings are consistent with the mechanism of action of AMB, and with the results described 
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above (Anderson et al., 2014). That is, the association of CST with L-AMB enhances the fungicidal 
activity of the latter, even at subinhibitory concentrations. Interestingly, our computational 
molecular dynamics studies have demonstrated that CST and L-AMB form a natural complex in 
solution, acting together on fungal cells. It is possible that the formation of this complex catalysis 
the assemble of AMB structure required for its fungicidal action (Gagós and Arczewska, 2010; 
Starzyk et al., 2014).  
Altogether, the presented results might represent a step forward in the management of 
invasive fungal infections treatment, for which, frequently liposomal amphotericin B is the only 
remaining therapeutic option. 
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This dissertation envisaged to explore the fungal cell mechanisms that allow the recovery 
from amphotericin B treatment, and to investigate strategies to improve the fungicidal activity of 
this drug. In this section, the scientific contribution of this dissertation will be discussed in 
conjunction with topics for future research.  
 
CONCLUDING REMARKS 
 
- The results presented in Chapter III demonstrated that the fungal response to L-AMB 
exposure clearly relates to the drug concentration. Accordingly, the yeast cell can respond in two 
ways, namely by: (i) expression of compensatory mechanisms as a response to drug-induced 
stress, and then, survival, whenever are initially exposed to high concentrations of L-AMB, and 
then to much lower concentrations for long periods of time; (ii) induction of programmed cell death 
and necrosis, whenever the cells are exposed to a constant high L-AMB concentration along the 
time. Therefore, the often-insufficient L-AMB concentration at the site of infection may 
compromise the L-AMB fungicidal action, allowing the increase of fungal burden, which ultimately 
may result in a poor clinical outcome.  
- In chapter III we also concluded that the mechanism of recovery from L-AMB action was 
common among pathogenic and non-pathogenic yeasts, and was a phenomenon independent of 
the MIC corresponding to the distinct fungal strains.   
- In chapter IV we detailed a novel method for the in vitro evaluation of antifungal 
associations, since this is an empirical and frequent practice, often encouraged by clinical 
therapeutic failure. This new methodology showed high sensitivity and specificity, and a good 
correlation with the traditional checkerboard method, providing results in less than 2 h.  
- The association of antifungal drugs with different mechanisms of action might represent 
a possible therapeutic option for the treatment of IFIs. In chapter IV, the association of 
anidulafungin with amphotericin B or azoles resulted in a synergistic effect in a vast amount of 
yeast isolates studied.  
- In Chapter V we demonstrated that the association of L-AMB with colistin improved the 
fungicidal activity of the first, and elucidated about the underlying mechanism of synergism, 
showing that these two drugs act together as a stable complex. Molecular dynamics study was 
an important tool for unveiling the mechanism of synergism.  
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- Flow cytometric assays were crucial for the development of the studies described in this 
dissertation. In chapters III e V this approach allowed to explore the mechanism of action of single 
L-AMB and in association with colistin. In chapter IV, FC was used to develop a new and reliable 
method to evaluate the in vitro antifungals association.  
 
FUTURE PERSPECTIVES 
 
 In the end of this dissertation, some questions remained unanswered and a few new ones 
came up. 
 We consider of relevance to corroborate the results obtained in vitro concerning the 
mechanism of yeast cells recovery at L-AMB plasma concentrations, and test the cidal effect of 
this drug at a constant fixed concentration, in an in vivo study. The confirmation of these results 
using an animal model, could lead to the design of new therapeutic regiments for the treatment 
of invasive fungal infections. Simultaneously, we would like to develop a novel tool for the 
therapeutic monitoring of L-AMB possibly based on flow cytometry, since its adoption in routine 
may increase the probability of a successful outcome. Notably, all the available methodologies 
are cumbersome, and therefore, impractical in the clinical routine.  
 Regarding the association of L-AMB with colistin, we would like to characterize the 
molecular interaction of the complex AMB:CST with the fungal membrane, and afterwards, to 
design a more active antifungal compound. The study of this interaction should involve molecular 
dynamics simulations (MDS), and be confirmed using knock-out strains for the best hits identified 
with MDS.  
In addition, we intend to explore further the association of L-AMB with other antibacterial 
agents. At the moment, the association between L-AMB and tigecycline is being characterized at 
a phenotypic and a functional level.  
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